Investigating the effect of phosphodiesterase inhibitors on human sperm motility and function by Rice, Anne
                                                                          
University of Dundee
MASTER OF SCIENCE
Investigating the effect of phosphodiesterase inhibitors on human sperm motility and
function
Rice, Anne
Award date:
2011
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jan. 2021
 
 
 
 
1 
Chapter 1: Introduction 
 
1.1 Development of Assisted Reproductive Technology (ART) 
 
Since its inception there has been a remarkable increase in the development and 
practice of ART including both in-vitro fertilisation (IVF) and intracytoplasmic 
sperm injection (ICSI) treatment (Figure 1.1). Correlated with an increase in the 
number of babies born following both IVF and ICSI treatment, ART has rapidly 
expanded in both its use and its acceptance (Tesarik et al., 1992). For example, the 
number of infants born from ART procedures (including IVF, ICSI, GIFT and ZIFT) 
has doubled from 30,629 in 1999 to 61,426 in 2008 (CDC, 2010). The revolutionary 
techniques of ART have allowed a solution for many couples. This progress includes 
an advance in the quality of treatment, such as the improvement of techniques used, 
from ICSI and surgical sperm retrieval to embryo cryopreservation. Due to such 
progress the success rate of ART has also increased. For example, the percentage of 
transfers resulting in live births increased from 11.5% in 1999 to 22% in 2008 for 
elective single embryo transfer (eSET) and from 30.9% in 1999 to 43.7% in 2008 for 
double embryo transfer (DET) (Figure 1.2). Although the success rate of ART has 
increased, the type of treatment provided depends on individual circumstances. Some 
of these circumstances include woman’s age or sperm quality as the cause of 
infertility. With ICSI representing almost half (47%) of all ART treatment in the UK 
in 2006, (Kurinczuk, 2010) this indicates that the male element is in fact the most 
common infertility problem between couples undergoing ART. However, there is 
limited knowledge of the causes of male infertility.  
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Figure 1.1 Interpretation of data from CDC (2010) ART Trends 1999-2008. 
Representing the number of all ART cycles (including IVF, ICSI, GIFT and ZIFT) 
performed compared with ICSI cycles alone using fresh non-donor oocytes in the 
US. 
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Figure 1.2 Interpretation of data from CDC (2010) ART Trends 1999-2008. 
Representing the percentage of elective SET and DET transfers resulting in live 
births using fresh non-donor oocytes in the US. 
 
 
1.2 Causes of male infertility 
 
Generally, infertility is viewed as a disease requiring medical treatment (Zegers-
Hochschild et al., 2009). Infertility is recognised as the inability of a couple to 
conceive after two years of contraceptive free intercourse (NICE). This may be 
divided into primary and secondary infertility. The latter being couples who have 
already had children and are unable to conceive. Nevertheless, both face the reality 
of infertility. On examining infertility trends over recent years, there is a rise in the 
occurrence of male factor infertility presented by the increase in ICSI (Figure 1.1). 
The number of ICSI procedures performed more than doubled from 28,090 in 1999 
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to 67,328 in 2008 in the US (CDC 2010). The most recent HFEA data also suggests 
that male factor infertility is predominantly the main diagnosis in patients seeking 
treatment compared to other factors (Figure 1.3). With further analysis, it would 
appear that ICSI is used more than expected and not only for male factor infertility. 
In the US in 2008, ICSI was carried out on 67,258 fresh non-donor cycles. Out of 
these cycles only 47.1% were diagnosed with male factor infertility with the majority 
(52.9%) having no male factor problems. However, procedures such as IUI, IVF or 
ICSI are dependent upon the parameters used for the diagnosis of male factor 
infertility. These vary between clinics and in turn, so do procedures. Results from 
ACU Ninewells in Dundee demonstrate the reality of male factor infertility. Male 
factor is primarily the reason for infertility from all ICSI cycles in 2010 with 84.7% 
embryo transfers originating from male factor infertility and only 6.9% female factor 
(Figure 1.4). These figures demonstrate a high proportion of male factor infertility in 
the ICSI population.   
 
The cause of male infertility is unknown in roughly 50% of cases (Oehninger and 
Franken, 2006). Various factors come under the heading of unknown and these 
elements of infertility are classed as unexplained. It is surprising that little is known 
as to what causes male infertility. The term ‘unexplained’ covers a range of sperm 
problems such as concentration, morphology, motility or sperm vitality. There are 
also abnormalities in sperm function, including the inability to bind to and penetrate 
the zona pellucida (Cahill and Wardle, 2002). For this the sperm must have 
progressive motility (Simon and Lewis, 2011) and the ability to acrosome react 
(Krausz et al., 1994) to enable successful sperm-oocyte interaction. Human sperm 
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motility defects are associated with 82% of cases with male infertility (Curi et al., 
2003; Chemes, 2000), yet little is known about the cause. 
 
 
 
Figure 1.3 Graph demonstrating reasons for patients undergoing infertility treatment 
in 2008 in the UK HFEA (2010). Data representing male factor infertility as the most 
common cause of infertility. 
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Figure 1.4 Interpretation of data from ACU Ninewells Hospital Dundee. Graph 
demonstrates the percentage of transfers from ICSI cycles by reason for infertility. 
Male factor includes various sperm abnormalities/failed vasectomy reversal, female 
factor includes tubal reasons/age/PCOS/anovulation/endometriosis, other includes 
previous failed fertilisation with IVF. 
 
 
1.3 Sperm motility 
 
Motility of a sperm cell is critical for fertility (Donnelly et al., 1998). In vivo, 
mammalian sperm must travel through the female reproductive tract to reach the site 
of fertilisation where fusion of male and female gametes takes place. In the female 
reproductive tract, sperm must accomplish the journey through a hostile, acidic 
environment, a barrier which is overcome by in vitro fertilisation. However, 
successful fertilisation in vitro is still dependent upon sperm motility (Simon and 
Lewis, 2011; Demir et al., 2011). 
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Sperm movement is generated by both the mid piece which consists of mitochondria 
to produce energy for sperm movement and the flagellum which propagates 
movement at the mid piece. The axoneme, a structure which runs through the sperm 
tail, moves in a way which causes flagellar waves propagating backwards to create 
forward propulsion (Mortimer, 1997). It consists of nine peripheral microtubule 
doublets and two central doublets which run the length of the flagellum and are 
protected by a cytoskeletal sheath (Inaba, 2003). Movement is achieved by the 
sliding of microtubule doublets by dynein arms (Mortimer, 2000). Dynein is 
responsible for converting chemical energy to mechanical energy from ATP 
hydrolysis for sperm motility. The sliding of microtubules creates bending and in 
turn, sperm motion. 
 
Protein phosphorylation is involved in the initiation and regulation of flagellar 
motility. One way in which sperm motility is generated is through cyclic adenosine 
monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP) signalling 
pathway. cAMP has long been known as a second messenger within cells and 
controls signalling pathways through the activation of protein kinase A (PKA) 
(Sutherland and Rall, 1960; Sutherland and Robinson, 1966; Sutherland et al., 1968). 
It is well established that cAMP and cGMP play an important role within human 
sperm involving motility and capacitation (Bajpai and Doncel, 2003). The level of 
cAMP within human sperm is therefore important regarding the fertilising potential 
of a sperm cell. A balance between inhibitory and stimulatory factors of cAMP is 
necessary to maintain the functional level. This balance exists due to the generating 
and degenerating processes of cAMP (Gagnon and De Lamirande, 2006). These 
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metabolic reactions include the synthesis of cAMP from adenosine triphosphate 
(ATP) mainly through soluble adenylate cyclase (sAC) and degradation by 
phosphodiesterases (PDEs) (Dessauer, 2009). The level of cAMP is therefore 
primarily controlled by the two enzymes sAC and PDEs along with external factors 
such as bicarbonate. sAC plays an essential role in the regulation of cAMP as 
without it, sperm are immotile and incapable of undergoing fertilisation (Esposito et 
al., 2004). Motility is generated through the activation of PKA by cAMP which is 
found within human sperm to phosphorylate substrate proteins giving rise to flagellar 
motility (Suarez, 2008). They are primarily involved in capacitation, the acrosome 
reaction and sperm function such as sperm-zona pellucida binding (Visconti and 
Kopf, 1998). It is therefore important that a balance exists in the level of cAMP to 
prevent premature hyperactivation, capacitation or acrosome reaction.  
 
 
1.3.1 Inhibition of sperm motility 
 
Contrary to this is the role of PDEs in human sperm. PDEs are known to breakdown 
cAMP. If too much cAMP is degraded, sperm motility may be interrupted, leaving 
sperm unable to function effectively. There are currently 11 different PDE gene 
families (Ghosh et al., 2009). PDEs are important regulators of signal transduction 
which degrade cyclic nucleotides i.e. the breakdown of the phosphodiester bond in 
cAMP and cGMP molecules. Both molecules are important in many biological 
processes, particularly the role of cAMP in mammalian sperm motility. It is well 
established that PDEs inhibit motility of human spermatozoa (Beavo, 1995). 
 
 
 
 
9 
Intracellular cAMP concentrations are regulated by stimulatory effects due to the 
permeability of the sperm cell. Stimulatory factors such as Ca2+ or HCO3- regulate 
these levels (Esposito et al., 2004). Changes in the level of cAMP, modulates activity 
of PKA resulting in a change of sperm motility. As cAMP is degraded it is converted 
into 5’AMP by PDEs (Figure 1.5). However, when produced by sAC, cAMP goes on 
to activate PKA which in turn activate PDEs. Functional levels of cAMP for sperm 
motility are not yet known however it is known that cellular functions within sperm 
are ultimately regulated by cAMP (Visconti et al., 1995). Subsequently, it is 
important that equilibrium between cAMP synthesis and degradation exists. 
Otherwise, the level of cAMP necessary for sperm motility may fluctuate. 
Consequentially, this may alter normal sperm function and in turn reduce the chance 
of a successful fertilisation.   
 
 
1.3.2 Stimulation of motility – interfering with cAMP using PDE inhibitors 
 
Since the early 1960s it was suggested that cAMP levels can be modulated by PDE 
inhibitors (Butcher and Sutherland, 1962). By the late 1960s it was known that the 
level of cAMP in sperm was important however the concept of enhancing cAMP 
using PDE inhibitors was only just being explored. A study by Yovich et al 1990 
showed a strong correlation between Pentoxyfilline (PTX), a non-specific PDE 
inhibitor and fertilisation rates. This was a clinical study carried out on 57 couples 
with 51 having both known male factor infertility and previous failed IVF attempts. 
There was a significant (P<0.001) increase in fertilisation rate of 47.4% compared to 
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20.4% when sperm were incubated with PTX. This study demonstrated a beneficial 
effect of PDE inhibitors on human IVF success rates. Following this, another 
landmark study was carried out in 1992 by Tesarik et al using PTX and caffeine, 
(caffeine is another non-specific PDE inhibitor) to enhance sperm motility. This 
study explored the risk of acrosome reaction induction when 22 sperm samples were 
incubated with PDE inhibitors separately. The acrosome reaction is an important step 
in sperm-oocyte interaction and if prematurely induced, the sperm may not bind to 
the oocyte (Buffone et al., 2008). The fertilising ability of sperm decreases when the 
acrosome reaction has taken place prior to oocyte penetration. This study 
demonstrated the addition of PTX has no effect on the rate of acrosome reaction. 
However, caffeine significantly increased the rate of induced acrosome reaction 
(using calcium ionophore A23187) after 1 hour addition. Inducing the acrosome 
reaction raised concerns about the efficiency of PDE inhibitors and the concept of 
inhibiting, rather than promoting fertilisation. In 1993 Tasdemir et al also showed 
that PTX added to a total of 11 patient samples with previous failed or low 
fertilisation prepared by the swim up method enhanced the acrosome reaction. The 
inhibitor at a final concentration of 2mg/ml was added along with the acrosome 
reaction inducer calcium ionophore (A23187) to observe any enhancement on 
induced reactions. Although in the previous study discussed, induction of the 
acrosome reaction is suggested as a negative factor on the fertilising ability of human 
sperm, this study showed a strong correlation between samples pre-treated with PTX 
and pregnancy rates. Group A consisted of those with previous successful 
fertilisation having a pregnancy rate of 27.3% when treated with PTX, a significant 
increase in IVF rate (P<0.001). Group B which consisted of those with previous 
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failed fertilisation, also had a significant increase in IVF rate (P<0.001) with a 
pregnancy rate of 45.4% when treated with PTX. From this study it may be said that 
PTX improves fertilisation, especially in cases with previous fertilisation failure.  
 
Tournaye et al 1993 however did not demonstrate a significant difference in 
fertilisation rates between groups of control and treated with PTX. This study 
included a total of 22 couples with male factor infertility and at least one previous 
IVF attempt resulting in failed fertilisation. No differences were noted in fertilisation 
rates between control and treated groups suggesting PTX does not benefit this group 
of patients. Notably, the sperm samples in this study were not prepared in the same 
way as studies such as Yovich et al 1990 where PTX was added after the wash rather 
than before in the case of this study. It is therefore possible that by washing sperm 
after the addition of a PDE inhibitor, its enhancing effect is lost and as a result, no 
improvement in fertilisation rates.  
 
Negri et al 1996 however used PTX during IUI sperm preparation in a group of 101 
cycles based on male factor infertility including asthenozoospermic and 
oligoasthenozoospermic patients. Patients used in this study had samples of normal 
morphology. The significance of incubating patient sperm with PTX was expressed 
by a rise in pregnancy rates (P<0.05). The standard preparation of sperm gave a 
pregnancy rate of 11.5% compared to 27.5% with samples treated with PTX out of 
61 and 40 cycles respectively. The results suggest PTX improves the motility of 
sperm. This is validated since the group treated with IUI for other reasons (including 
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anovulation and endometriosis i.e. not male factor infertility) did not show any 
improvement in pregnancy rates when samples were treated with PTX.  
 
The results of improving sperm for IUI are supported by a retrospective analysis 
study on 9963 IUI cycles (Stone et al., 1999). The aim of this study was to determine 
factors which influence the effectiveness of IUI including various methods of sperm 
sample preparation. One means of sperm preparation included the use of PTX as a 
motility enhancer demonstrating a higher overall pregnancy rate of 17.1% when 
sperm samples were suspended in culture media containing a final concentration of 
3mmol/L PTX before Percoll processing. This is compared to 11% without the 
addition of any PDE inhibitor. Previous studies have included relatively small study 
groups whereas this study involved statistical analysis on a much larger scale and 
would therefore be more reliable. However, due to this and the exploration of 
different techniques of sperm preparation, this study is complex and does not 
concentrate specifically on the detail of PDE inhibitor addition. 
 
Recent studies have demonstrated positive results using PTX. Mangoli et al 2011, 
used PTX for viability testing on non-motile sperm from testicular biopsies. This 
study compared PTX to the Hypo-osmotic swelling test (HOS), a well known 
viability test. They found an increase in pregnancy rates and fertilisation rates using 
PTX (32% and 62.05% respectively) compared to HOS test (16% and 41.07% 
respectively) to identify viable sperm. The HOS test has however been extensively 
studied and is known to be an easy, inexpensive and reliable method of sperm 
viability testing (Tartagni et al., 2004). This questions the need for another viability 
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test. However, recent studies have shown that PTX improves sperm motility 
(Kovacic et al., 2006). This study analysed 77 cycles of testicular sperm extraction 
(with ICSI) split into control group of 30 (without PTX) and treated group of 47 
(sperm treated with PTX for 20 minutes). Immotile sperm from testicular samples 
became motile with exposure to PTX (1.76mM) for only 20 minutes. Fertilisation 
and pregnancy rates were higher for PTX treated cycles (66% and 38.3% 
respectively) than the control group (50.9% and 26.7%). Based on these results the 
authors concluded that PTX facilitates easy detection of viable sperm for use in ICSI. 
These studies are significantly important as it is known that the use of non-motile 
sperm increases the incidence of mitotic spindle defects (Tasdemir et al., 1998), 
which may be damaging to any resulting embryos or children born. However the 
subject of sperm viability testing prior to ICSI procedure is controversial due to the 
risk of damaging the limited sperm available. In response to the latest study by 
Mangoli et al 2011, Malpari et al state that there is no need to risk damage using 
PTX since sperm from biopsies are always viable even if immotile. This is because 
the testes only produce live cells and therefore no need to subject sperm to any 
testing which could potentially damage the cells. However, if this was the case it 
would be reasonable to assume all sperm would have fertilised mature oocytes 
(Kovacic, 2006).  
 
Whilst studies both old and new have shown PTX amongst other PDE inhibitors 
have a significant effect on sperm motility, these inhibitors are not specific to certain 
individual PDEs and may inhibit more than one PDE type. Although sperm motility 
may be enhanced, any side effects of adding PDE inhibitors which are non-specific 
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remain unclear. Sildenafil is a PDE inhibitor which is known to be specific to PDE-5 
(Corbin et al., 2003). It is commonly known as Viagra and in inhibiting PDE-5, 
increases levels of cGMP. A study carried out by Glenn, 2009, investigated the effect 
of using sildenafil in mice to determine fertilisation and embryo development. Male 
mice were fed sildenafil and allowed to mate with females injected with human 
chorionic gonadotropin (hCG). After female mice were killed their oviducts were 
dissected and embryos retrieved for assessment. They found a significant (P<0.001) 
decrease in fertilisation on day 1 by 33% where the male had taken sildenafil. They 
also found fewer embryos developed from all 4 days of killing where the male had 
taken sildenafil. For example, out of 21 mice killed without sildenafil the mean 
number of embryos was 23.1(+/-6.1) compared to 15.9(+/-4.8) with sildenafil, both 
goups killed on day 4, statistics are not given here. This study indicates a detrimental 
effect with the use of PDE inhibitors. Reasons for this may include alterations to 
sperm function such as the acrosome or the cause of sperm or embryo DNA damage 
(some of which will be explored in this study) or the inability of sperm/embryos to 
repair DNA damage. The fact that the number of motile sperm increases with PDE 
inhibitors along with the increased velocity would suggest more sperm reach the 
oocyte and therefore more chance of fertilisation. PDE inhibitors may counteract the 
positive effect on sperm motility by altering normal sperm function such as binding 
to or penetrating the oocyte. Recent studies have investigated the effect of PDE 
specific inhibitors on sperm motility. However, the use of PDE inhibitors on human 
sperm is controversial due to the limited amount of data available. From the 11 PDE 
families recognised to date, each have different isoforms. Individual PDEs differ in 
their type of regulation, sensitivity and localisation. Many types of PDEs can be 
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expressed in a single cell type which may also be the main regulators of cAMP and 
cGMP within a cell. This regulation can occur as biochemical interactions such as 
binding of Ca2+-calmodulin (Ca2+/CaM) and other protein interactions. Inhibitors 
control the temporal duration of cyclic nucleotides in the cell ensuring a local supply 
for the cell to function efficiently and at the same time not too much that will 
overload the cell (Houslay, 2010). The problem with PDE inhibitor control however 
is non specificity of some PDE inhibitors. Early studies have suggested that nearly 
all PDE inhibitors would inhibit most PDE types in a cell. Recent research however 
has recognised PDE inhibitors which are specific to a PDE type and should only 
influence the activity of that PDE (Bender and Beavo, 2006). It is for this reason 
PDE inhibitors have been used clinically. There is also belief that PDE type specific 
inhibitors can be developed to selectively target specific isoforms. The value of this 
is to avoid any occurring side effects that a non-specific inhibitor could cause. 
However due to limited data regarding type specific PDE inhibitors, little is known 
about the localisation and activity of PDEs within human sperm. 
 
PDEs recognised in human sperm include PDE-1, 3, 4, 5 (Lefievre et al., 2002; Fisch 
et al., 1998; Cuadra et al., 2000). PDE-1 and 4 were some of the first PDE types 
suggested to be present in human sperm through the use of PDE type specific 
inhibitors. Fisch et al 1998, demonstrated that an inhibitor of Ca2+/CaM regulated 
PDE-1, 8-methoxy-isobutylmethylxanthine (8-MeOM-IBMX) at a final 
concentration of 100µM and cAMP-specific PDE-4, RS-25344 (Rolipram) at a final 
concentration of 10 µM had significant effects on human sperm activity. Firstly they 
showed that 35-40% and 25-30% of PDE activity was 8-MeOM-IBMX and 
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Rolipram sensitive respectively suggesting PDE-1 and 4 are present in human sperm. 
Their data also demonstrates that 95% of PDE activity is IBMX sensitive which 
supports the fact that IBMX is non-specific compared to PDE-1 and 4 inhibitors 
which are selective. They then demonstrated that sperm motility can be enhanced 
using Rolipram on 27 healthy donor sperm samples after a 2 hour incubation period. 
This result was significant (P<0.0001) even in the donor population as the average 
motility increased from 71.1%(+/-1.9) in the control group compared to 76.1%(+/-
1.3) in the treated group. A significant (P=0.00008) increase in sperm motility was 
also observed using 12 abnormal samples with average motility increasing from 
65.6%(+/-2.0) to 74.3%(+/-1.5) in the treated group. There was however no 
significant change in motility using 8-MeOM-IBMX on either sperm sample group. 
When investigating the effect of PDE inhibitor on the acrosome reaction they 
observed 8-MeOM-IBMX selectively stimulated the acrosome reaction whereas 
Rolipram did not. This evidence supports the hypothesis that PDE subtypes do exist 
within human sperm and inhibiting them may affect sperm activity. 
 
PDE-1s were one of the first of the PDE family to be located within the human 
sperm cell (Lefievre et al., 2002). PDE-1A (an isoform of PDE-1) was localized on 
the equatorial segment of the sperm head as well as on the mid and principal pieces 
of the flagellum by immunocytochemistry experiments using isoform specific 
antibodies. PDE-3A (an isoform of PDE-3) was also located on the post acrosomal 
segment of the sperm head. However, there is limited information on the effect of 
inhibition of specific PDEs within human sperm.  
 
 
 
 
 
17 
Recent development in PDE targeting has been investigated in other cell types 
(Witzenrath et al., 2009; Rahrmann et al., 2009). PDE inhibitors are commonly used 
drugs with various uses in medicine. They are already used clinically for a range of 
diseases and disorders and have been proven safe for use. Type specificity is of 
crucial importance to eliminate the possibility of other PDEs being inhibited and in 
turn causing detrimental effects. PDE inhibitors are commonly used as therapeutic 
solutions to a variety of disorders. They range from cognitive disorders such as 
schizophrenia and dementia (Zhang, 2010) to inflammatory disorders such as asthma 
and bladder inflammation (Kitta et al., 2008). Others include the PDE-5 inhibitor 
commercially known as sildenafil (as discussed previously), which increases the 
availability of cGMP in the cell, and is not only used as an erectile dysfunction drug 
but may also be a possible solution to heart failure (Guazzi et al., 2010). Others 
specific to their corresponding PDEs include BRL, specific to PDE-7 and Papaverine 
specific to PDE-10. BRL is used in airway and immunological applications since 
PDE-7 has been expressed in human proinflammatory and immune cells (Smith et 
al., 2004). This study also demonstrated that BRL failed to inhibit other PDEs such 
as PDE-1, PDE-2 and PDE-5, thus providing encouraging results for the clinical use 
of this inhibitor. Papaverine is used for schizophrenia and other neurological 
disorders (Ghosh et al., 2009). This PDE inhibitor is reported to be specific to PDE-
10 and related to Huntington’s Disease (Hebba et al., 2004).  
 
Recent advances in the field of PDE research have rekindled interest in the clinical 
advantage of PDE inhibitors. However, even with positive results it is surprising that 
little is known about the effect of type specific inhibitors on sperm; particularly since 
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non-specific inhibitor studies have shown to have a positive effect on sperm motility. 
However, there is no information regarding the effect of PDE inhibitors on human 
sperm function at the sperm-oocyte interaction stage. Although, PDE inhibitors are 
reported to have a positive effect on sperm motility it is important that this is 
maintained throughout the stages of fertilisation. It is also important that PDE 
inhibitors do not cause any detrimental effects to the sperm-oocyte interaction or the 
development of any resulting embryos.   
 
 
1.4 Sperm-oocyte interaction 
 
Although type specific PDE inhibitors have been used to influence the motility of a 
sperm cell, they have never been used to test sperm function such as the interaction 
between sperm and oocyte including penetration of the cumulus, binding to the zona 
pellucida and fusing with the oolema. Since sperm motility can be enhanced using 
PDE inhibitors there is a possibility that sperm function may be restored i.e. such as 
the ability to acrosome react or bind to the zona pellucida. Enhancing or even 
restoring the function of defective sperm could result in an increase of ICSI to IVF 
(or even further to IUI) conversions for patients. Thus reducing treatment cost for the 
patient, invasiveness of the oocyte (or patient in the case of IUI) and an 
embryologists time required to carry out the ICSI procedure. Improving sperm 
function at the sperm-oocyte interaction stage suggests an increase in fertilisation and 
pregnancy rates for ART clinics since firm attachment of gametes has previously 
predicted IVF outcome (Liu et al., 2011). However, there is no information regarding 
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the effect of PDE inhibitors on human sperm-oocyte interaction, hence no correlation 
between PDE inhibitors and sperm function at this critical stage.  
 
Motility is known as one of the key predictors of fertilisation outcome as it predicts 
cumulus and zona pellucida penetration by the sperm cell (Oehninger, 1992). The 
interaction between sperm and oocyte is a critical event leading to fertilisation. 
Multiple sperm functions are reflected by this step including the ability of the sperm 
to bind to the zona pellucida, undergo acrosome reaction and fuse to the oolema 
(Suarez et al., 2006). Motility is also important for sperm to generate propulsive 
forces which are necessary to penetrate the zona pellucida (Mortimer, 1997). A way 
of predicting the effect of PDE inhibitors on penetration and overall fertilisation 
would be investigating the ability of sperm to bind to the zona pellucida. Sperm-zona 
pellucida binding is arguably the most important stage of fertilisation and has been 
investigated since the late 1980s (Franken et al., 1989). Two types of sperm-zona 
pellucida binding tests have previously been used as predictors of fertilisation in 
vitro including the hemizona assay (HZA) and sperm-zona pellucida binding test. 
These studies have shown a significant correlation with fertilisation rates providing a 
diagnostic tool for patients undergoing IVF treatment (Franken et al., 1989). 
Following this, recent studies have also suggested the use of zona pellucida bound 
sperm for treatment (Liu et al., 2011). Other studies have suggested the use of sperm-
zona pellucida binding as a diagnostic tool in order to predict and prevent failed 
fertilisation (Lee et al., 2008). Some have even suggested that the sperm-zona 
pellucida method has the potential as a contraceptive intervention (Dun et al., 2010). 
Overall, the sperm-zona pellucida binding test is viewed as a reliable and useful 
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method for determining the quality and ability of a sperm cell. Investigating sperm 
function at the fertilisation level by the inhibition of PDEs is a major step in the 
advances of ART and may provide useful clinical information. PDE inhibitors are 
therefore a growing interest as targets for therapeutic intervention.  
 
 
1.5 Aims and objectives 
 
The principle aim of this study was to investigate the effect of PDE inhibitors on 
human sperm motility and function. Experiments were carried out using CASA and 
various sperm function tests with a variety of PDE inhibitors. ART patients were 
used in this study to determine whether PDE inhibitors have any clinical beneficial 
effects. The aim of this was to provide a better understanding of the effect of PDE 
inhibitors on patient sperm, in turn providing a clinical insight into the effect of PDE 
inhibitors.  
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Figure 1.5 Personal interpretation of cAMP dependent pathway. Figure demonstrates 
the action of PDE in the synthesis of cAMP to 5’AMP. 
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Chapter 2: Investigating the effect of PDE-1 and PDE-4 specific inhibitors on 
human sperm motility 
 
2.1 Introduction 
 
PDE-1 and PDE-4 have been studied extensively in various cell types. However, not 
many studies have investigated the existence and function of these PDEs in sperm. 
Few studies have examined PDE-1 and PDE-4 in sperm with their corresponding 
inhibitors 8-MeOM-IBMX and Rolipram respectively.  
 
PDE-1 was one of the first PDE families to be identified and has been extensively 
studied in other cell types. PDE-1 has three different isoforms, PDE-1A, PDE-1B 
and PDE-1C. PDE-1 is regulated by Ca2+/CaM which stimulates cyclic nucleotide 
hydrolysis. The PDE-1 enzymes can hydrolyse both cAMP and cGMP however the 
affinity for each nucleotide varies depending on which isoform. PDE-1 isoforms 
have been expressed in the brain and peripheral neurons, the heart and cardiovascular 
vessels and the macrophages and T lymphocytes of the immune system (Medina, 
2011; Movsesian and Kukreja, 2011; Kanda and Watanabe, 2001). More relevant to 
this study however, PDE-1 is has been located in the human testis (Fidock et al., 
2002) and in sperm with most activity found in the mid-piece and tail (Lefievre et al., 
2002). Previous studies demonstrated the presence of PDE-1A and PDE-1C using 
immunocytochemistry in germ cells in the mouse testis (Yan et al., 2001). These 
PDE forms were highly expressed in developing and mature sperm suggesting PDE-
1 has a role in spermatogenesis with the expression of PDE-1 forms relating to the 
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different stages in development. In 2002, Lefievre et al demonstrated the presence of 
PDE-1A along with PDE-3A in the equatorial section and flagellum, and sperm head 
respectively of human sperm. These results gained through immunoblotting, 
confirmed the presence of PDE-1 isoforms in human sperm. This group go on to 
suggest PDE-1A is permanently active in sperm since Ca2+/CaM is tightly bound to 
PDE-1A and cannot be dissociated. The presence of more than one PDE-1 isoform 
was confirmed in 2005 as Vasta et al identified a new variant of PDE-1A in mouse 
sperm using immunocytochemical staining. PDE-1A revealed intense expression in 
the sperm tail. These results suggest that more than one PDE isoform is active in 
sperm and a step further to understanding the role of PDEs in regulating sperm 
function.  
 
PDE-4 is expressed in various cell types and plays major roles in many biological 
processes. There are four genes PDE-4A, PDE-4B, PDE-4C and PDE-4D that make 
up the PDE-4 family (Bender and Beavo, 2006). PDE-4 is one of the most studied 
PDEs in various cell types with extensive information available on its physiological 
function. PDE-4 is recognised to have cAMP specific activity which is characterised 
when inhibited by the PDE-4 selective inhibitor known as Rolipram. PDE-4 has been 
associated with various diseases such as heart disease, since cAMP is a regulator of 
cardiac contractility. Studies using PDE knock-out mice give a valuable insight into 
the importance of PDEs. For example, PDE-4D deficient mice have progression of 
heart failure (Lehnart et al., 2005). Jin and Conti in 2002 investigated PDE-4B 
knock-out mice which demonstrated the importance in immune cells as PDE-4B 
deficient mice did not show an inflammatory response to lipopolysaccharide in 
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monocytes. These studies clearly indicate individual PDEs are related to different 
functions and emphasises the importance for type specific inhibitors if used 
clinically. The evidence of PDE-4 in sperm however is very limited. Some studies 
have investigated the effect of PDE-4 inhibitor Rolipram (Fisch et al., 1998). 
However, there appears to be no recent development or further investigation. This 
section investigates the effect of 8-MeOM-IBMX and Rolipram on the percent of 
motile cells of donor and patient sperm samples.  
 
 
2.2 Materials and Methods 
 
Experiments were carried out on a pool of either sperm donors with no known 
fertility problems or sperm samples from patients undergoing IVF/ICSI. The mean 
percent of motile cells was the focus in this study. After density gradient 
centrifugation, both the 40% and 80% fractions were used from donor samples and 
only the 40% fraction used from patient samples as the 80% was not available at this 
time. The 80% pellet contains the more dense mature sperm with a higher percentage 
of progressively motile cells whereas the 40% is known to contain the less motile, 
immature sperm (Kessopoulou et al., 1992). The difference between the separate 
fractions with regards to the percentage of motile sperm has been correlated with 
fertilisation and pregnancy rates (Donnelly et al., 1998). In this study both fractions 
were investigated where possible to gain a better understanding of the contrast of 
motility within different fractions and the true effect of PDE inhibitors.  
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2.2.1 Sperm Preparation 
 
2.2.1.1 Donor Sperm Preparation 
 
Semen samples were obtained from three consented ‘healthy’ donors. Samples were 
produced at home after 2-5 days of sexual abstinence and collected in sterile 60ml 
containers. Samples were obtained within 1 hour of production and incubated at 
37°C until liquefied. An initial assessment of sperm concentration and motility was 
carried out in order to investigate the quality of the individual samples using CASA 
(Computer Assisted Sperm Analysis) by placing 4µl of the raw sample on a 20µm 
depth Hamilton-Thorne slide with a 22mm by 22mm coverslip. Up to 2mls (where 
possible, dependant on sample volume) of semen sample was then layered on a 
PureSperm® gradient of 40% and 80% in a non-sterile 15ml conical bottom falcon 
tube. Centrifugation was carried out at 300g for 20 minutes. The supernatant was 
discarded and either the 40% fraction or the pellet was then taken by a Pasteur 
pipette and placed into a non-sterile 15ml conical bottom falcon tube containing 5mls 
HEPES buffered Earle’s medium (1.8mM CaCl2, 5.37mM KCl, 0.81mM MgSO4, 
1.01mM NaH2PO4, 116.36mM NaCl, 5.55mM D-Glucose, 2.73mM C3H3NaO3, 
41.75mM NaC3H5O3, 25mM HEPES pH 7.4). Each fraction was centrifuged at 500g 
for 10 minutes allowing the sperm to be ‘washed’, removing any remaining 
PureSperm®. Pellets from both fractions were suspended in 500µl pre-equilibrated 
synthetic tubal fluid (STF) medium (3.0mM CaCl2, 4.7mM KCl, 1.0mM MgSO4, 
106.0mM NaCl, 1.5mM NaH2PO4, 5.6mM D-Glucose, 1.0mM C3H3NaO3, 41.8mM 
C3H5NaO3, 1.33mM Glycine, 0.68mM Glutamine, 0.07mM Taurine, 25mM 
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NaHCO3, pH 7.4 supplemented with 30mg/ml human serum albumin). The fractions 
were then incubated at 37°C with 6% CO2 for at least 3 hours in order for the 
samples to capacitate. Sperm concentration and motility were assessed from both the 
40% and 80% suspensions using CASA and a dilution made to the required sperm 
concentration of approximately 20x106/ml. Sperm morphology was not carried out in 
this study. Both 40% and 80% fractions were assessed.  
 
 
2.2.1.2 Patient Sperm Preparation 
 
Samples were obtained from three Ninewells Hospital Assisted Conception Unit 
(ACU) patients consented for this study. Patient samples were produced in the ACU 
and allowed to liquefy in a 37°C incubator within 30 minutes allowing the sperm to 
become freely motile. Sperm preparation for IVF/ICSI treatment was carried out in 
the ACU by an embryologist and any surplus of raw sample was used in this study. 
An initial assessment of sperm concentration and motility were carried out to 
investigate the quality of the individual samples using CASA as above. The samples 
were prepared as above however only the 40% fraction was used from patient 
samples. The pellets were suspended as above in media depending on whether they 
were IVF or ICSI. IVF samples were suspended in pre-equilibrated 500µl synthetic 
tubal fluid (STF) medium and ICSI samples in HEPES buffered Earle’s medium. 
IVF samples were then incubated at 37°C with 6% CO2 for at least 3 hours in order 
for the samples to capacitate whereas ICSI samples were left at room temperature. 
Sperm concentration and motility were assessed from the suspensions and a dilution 
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made to the required sperm concentration of approximately 20x106/ml in their 
corresponding media. Sperm morphology was not included in this study. Only the 
40% fraction was assessed. 
 
 
2.2.2 Sperm-PDE inhibitor incubation 
 
Following sperm preparation and capacitation (see 2.2.1.1 and 2.2.1.2), 99µl of each 
sample was placed into 1.5ml eppendorfs of control and treated. The treated labelled 
eppendorf was then supplemented with 1µl of a selected PDE inhibitor (8-MeOM-
IBMX and Rolipram used in this section) making up to a required final 
concentration. PDE inhibitor concentrations were selected according to previous 
literature (see table 2.1). Inhibitors 8-MeOM-IBMX, Milrinone and Rolipram were 
used at concentrations previously studied whereas the concentration of Papaverine 
and BRL (PDEs which have not been explored in human sperm) was used as a 
starting point to gain an insight into whether there is any effect of these inhibitors on 
human sperm motility. Eppendorf lids were pierced to allow entry of CO2. PDE-1 
and 4 specific inhibitors (8-MeOM-IBMX and Rolipram respectively) were used at 
concentrations of 100µM and 10µM respectively (Fisch et al., 1998). Table 2.1 
demonstrates the inhibitors selected for use throughout the study and the final 
concentrations at which they were used: 
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PDEI PDE Type Final Concentration 
(µM) 
8-MeOM-IBMX PDE-1 100 
Milrinone PDE-3 50 
Rolipram PDE-4 10 
BRL PDE-7 100 
Papaverine PDE-9 100 
 
Table 2.1 PDE inhibitors and their corresponding final concentrations used in this 
study. Concentrations based on previous studies (Fisch et al., 1998; Lefievre et al., 
2002). 
 
 
Samples were incubated with a selected PDE inhibitor at 37°C, 6% CO2 for a select 
time period (0.5, 1 and 2hr in this section). After gentle mixing, 4µl was taken from 
each aliquot (control and treated) for analysis and placed on a 20µm depth Hamilton-
Thorne slide with a 22mm by 22mm coverslip after the slide was left on a heated 
stage for 1 minute, to allow temperature equilibration. The percent of motile sperm 
was assessed using CASA as this is one of the most significant predictors of fertility, 
alongside sperm concentration (Larsen et al., 2000). Parameters used to determine 
sperm characteristics pre and post PDE inhibitor addition are shown in table 2.2. 
ANOVA was used in statistical analysis to compare the mean of both control and 
treated over several incubation time points and P value <0.05 was considered 
significant. 
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Terminology Definition 
Static No movement 
Slow <5 µms-1 VAP 
Medium 5-25 µms-1 VAP 
Rapid >25 µms-1 VAP 
Motile Rapid + medium + Slow 
Progressive motility VAP > 25 µms-1 
STR > 80% 
 
Table 2.2 Standard CASA parameters used to analyse human sperm motility. Percent 
of motile sperm includes slow, medium and rapid cells. Progressively motile cells (as 
used in later chapter) includes those with an average path velocity (VAP) of greater 
than 25 µms-1 and a linearity of greater than 80%. 
 
CASA 
CASA is an automated digital system which can analyse motility characteristics and 
predict the fertility potential of sperm (Youn et al., 2011). Early generation CASA 
systems were only suitable for research purposes due to their inaccuracy in semen 
analysis (Mortimer and Mortimer, 1988), however the development of CASA has led 
to a clinical application. The advantages of CASA over manual semen analysis first 
include the accuracy of assessing subtle movement characteristics of sperm which 
cannot be done by eye including velocity. Secondly, CASA can be carried out in a 
matter of seconds, measuring hundreds of cells, again impossible to do manually. 
The use of CASA in this study was decided upon and used throughout due to these 
factors and for the purpose of standardisation.  
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How CASA works 
In this study, a Hamilton Thorne 'CEROS' computer assisted sperm analyser was 
used with negative phase contrast and charged couple device (CCD) video camera 
showing white sperm against a dark background. This was combined with the 
clinical human application (Version 12). As the camera scans the image it combines 
fields to form a frame and in this study a frame rate of 60Hz was used to reconstruct 
an accurate measurement of sperm movement as recommended for the analysis of 
human sperm (Owen and Katz, 1993). Images from a microscope field are converted 
into a digital image by the camera from the size and illumination of sperm heads and 
a trajectory for each cell can be reconstructed (Mortimer, 1997). Although sperm 
motility largely depends on the flagellum, it is not possible to gain a clear image of 
this structure and so it is easier to analyse sperm head movement. Trajectories 
provide information on sperm motility and are one of the main advantages of CASA 
since manual trajectory reconstruction would be difficult to achieve. Included in this 
are three velocity parameters. Straight line velocity (VSL) is the distance between the 
start and the end of sperm trajectory, in other words, the distance covered in a 
straight line. The curvilinear velocity (VCL) is the measure of the overall distance 
travelled in any direction. The average path velocity (VAP) is the length of the 
general trajectory which is the distance of the average direction of movement. Values 
derived from the velocity parameters include the linearity ((VSL/VCL)x100) and 
straightness ((VSL/VAP)x100) which allow a more detailed analysis of movement 
and distinction between types of motility. Other parameters include the amplitude of 
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lateral head displacement (ALH) and beat cross frequency (BCF) which measure the 
movement of the sperm head from side to side and the flagellar beat respectively.  
 
Relevant motility parameters   
Since sperm move in ways that are adapted to their functional needs, the parameters 
chosen to represent the questions in this study include percent motile cells, percent 
progressively motile cells and the average path velocity. Firstly the percent of motile 
cells is an important element of IVF insemination and is defined by the total of rapid 
and medium cells, in other words with a speed of above 5µm/s (Table 2.2). Secondly, 
the percent of progressively motile cells which is important particularly for IUI 
where sperm have a greater distance to swim. This is defined by an average path 
velocity of greater than 25µm/s and a straightness of more than 80% which is 
calculated by the straight line velocity and average path velocity. The average path 
velocity is the velocity along the average path of the sperm and is another 
parameter which involves the progression of a sperm cell. Velocity is important for 
the penetration of cervical mucus and sperm-egg interaction. 
 
Clinical application of CASA 
Studies have shown the clinical potential of CASA with the relationship between 
sperm movement and fertilisation potential of both the general population and those 
with unexplained infertility (Larsen et al., 2000; Youn et al., 2011) and those 
specifically with male fertility problems (Aitken et al., 1984; Barratt et al., 1993; 
Paston et al., 1994; Krause, 1995). The various parameters of sperm motility allow 
the prediction of the function ability of sperm such as penetration of cervical mucus 
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or penetration of the zona pellucida, both important factors in fertilisation and both 
investigated in this study.  
Although evidence suggests a link between the use of CASA and fertility, there is a 
lack of standardisation between laboratories. One of the major issues surrounding 
this is the definition of specific motility parameters such as hyperactivation which 
will not be investigated here (Mortimer, 1997). Others include the effects of sperm 
preparation technique and culture conditions between laboratories, making it difficult 
to compare studies. There are also various makes and models of CASA which have 
discrepancies between them. However, studies have still shown significance with the 
use of CASA and fertilising ability of sperm within their settings. 
 
 
2.3 Results: Effect of PDE inhibitors on sperm motility 
 
2.3.1 Effect of PDE inhibitors on ‘healthy’ donor population  
 
There was no significant increase in the percent of motile cells in either 8-MeOM-
IBMX or Rolipram treated 80% fractions of donor sperm (figures 2.1 and 2.2). The 
results at 0.5, 1 and 2 hours incubation between control and treated were not 
statistically significant (P > 0.05).  
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Figure 2.1 Each bar represents the mean percent of motile cells in the 80% fraction 
of 3 different donor sperm samples at 0.5, 1 and 2 hours incubation with and without 
the addition of 8-MeOM-IBMX. P>0.05 therefore no statistical difference between 
the control and treated at any time point.  
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Figure 2.2 Each bar represents the mean percent of motile cells in the 80% fraction 
of 3 different donor sperm samples at 0.5, 1 and 2 hours incubation with and without 
the addition of Rolipram. P>0.05 therefore no statistical difference between the 
control and treated at any time point. 
 
The results also demonstrate no significant difference in the percent of motile cells 
when the 40% fraction of donor sperm is incubated with either 8-MeOM-IBMX or 
Rolipram at 0.5, 1 and 2 hour incubation periods (P > 0.05) (Figures 2.3 and 2.4). 
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Figure 2.3 Each bar represents the mean percent of motile cells in the 40% fraction 
of 3 different donor sperm samples at 0.5, 1 and 2 hours incubation with and without 
the addition of 8-MeOM-IBMX. P>0.05 therefore no statistical difference between 
the control and treated at any time point. 
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Figure 2.4 Each bar represents the mean percent of motile cells in the 40% fraction 
of 3 different donor sperm samples at 0.5, 1 and 2 hours incubation with and without 
the addition of Rolipram. P>0.05 therefore no statistical difference between the 
control and treated at any time point. 
 
 
2.3.2 Effect of PDE inhibitors on patient samples 
 
After 1 hour incubation with 8-MeOM-IBMX there was a significant increase in the 
percent of motile cells in the 40% fraction of three patient samples (Figure 2.5). 
There was also a significant increase in the percent of motile cells when the 40% 
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fraction of patient samples were treated with Rolipram at 0.5, 1 and 2 hour 
incubation periods (Figure 2.6).  
 
Figure 2.5 Each bar represents the mean percent of motile cells in the 40% fraction 
of 3 different patient sperm samples at 0.5, 1 and 2 hours incubation with and 
without the addition of 8-MeOM-IBMX. P<0.05 at 1 hour incubation time therefore 
a statistical difference between the control and treated. 
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Figure 2.6 Each bar represents the mean percent of motile cells in the 40% fraction 
of 3 different patient sperm samples at 0.5, 1 and 2 hours incubation with and 
without the addition of Rolipram. P<0.05 throughout incubation times and therefore 
a statistical difference between the control and treated. 
 
The difference between the quality of 40% fractions of donor and patient sperm was 
clear with regards to motile sperm, even without the addition of PDE inhibitors. For 
example, after 1 hour incubation the mean percent of motile cells in the control 
population of donor sperm was 62.4% ± 6.1 compared to16.5% ± 9.0 for the control 
population of patient sperm (See tables 2.3 and 2.4 for further details). This table 
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demonstrates that the target population for improving motility is patient sperm 
samples. 
 
 
Time (hours)  40% fraction 
treated with 8-
MeOM-IBMX 
Motility 
Mean % ± 
SEM 
P-value 
0.5 Donor  C 
T 
Difference 
68.8 ± 10.7 
64.8 ± 13.8 
4 ± 3.1 
0.47 
 Patient C 
T 
Difference 
16.3 ± 8.6 
29.2 ± 13.0 
12.9 ± 4.4 
0.2 
1 Donor  C 
T 
Difference 
62.4 ± 6.1 
59.2 ± 3.9 
3.2 ± 2.2 
0.13 
 Patient C 
T 
Difference 
16.5 ± 9.0 
32.6 ± 13.4 
16.1 ± 4.4 
0.036 
2 Donor  C 
T 
Difference 
85.9 ± 6.7 
83.8 ± 5.1 
2.1 ± 1.6 
0.28 
 Patient C 
T 
Difference 
16.8 ± 9.6 
27.9 ± 15.6 
11.1 ± 6 
0.37 
 
Table 2.3 Effect of 8-MeOM-IBMX on the percent of motile cells in the 40% 
fraction of donor and patient human sperm samples. CASA performed at 0.5, 1 and 2 
hours.  
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Time (hours)  40% fraction 
treated with 
Rolipram 
Motility 
Mean ± SEM 
P-value 
0.5 Donor  C 
T 
Difference 
68.8 ± 10.7 
68.9 ± 13.4 
0.1 ± 2.7 
0.96 
 Patient C 
T 
Difference 
24.1 ± 7.4 
46.3 ± 2.8 
22.2 ± 4.6 
0.03 
1 Donor  C 
T 
Difference 
62.4 ± 6.1 
65.1 ± 13.5 
2.7 ± 7.4 
0.61 
 Patient C 
T 
Difference 
28.8 ± 11.3 
45.6 ± 9.9 
16.8 ± 1.4 
0.02 
2 Donor  C 
T 
Difference 
55.3 ± 15.2 
52.3 ± 15.3 
3 ± 0.1 
0.08 
 Patient C 
T 
Difference 
16.1 ± 5.8 
46.6 ± 1.2 
30.5 ± 4.6 
0.009 
 
Table 2.4 Effect of Rolipram on the percent of motile cells in the 40% fraction of 
donor and patient human sperm samples. CASA performed at 0.5, 1 and 2 hours. 
 
 
2.4 Discussion  
 
PDE-1 and 4 inhibitions (8-MeOM-IBMX and Rolipram respectively) do not have 
any significant effect on the percent of motile cells of the 80% fraction of donor 
sperm samples. Reasons for this may be that sperm from a good quality sample 
cannot be improved. There was also no effect on the 40% fraction of donor sperm. 
The quality of a 40% fraction is generally poorer than that of an 80% fraction from 
sperm preparation and so it would be expected that the 40% fraction may be 
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improved (Mortimer, 2000). However, this was not the case with the samples used in 
this study. Reasons for this may be that the samples were of such good quality that 
even the 40% fraction was not as poor as expected. In contrast, patient samples were 
poor with regards to the percent of motile sperm and therefore were improved. The 
percent of motile cells was initially relatively low and increased with the addition of 
either 8-MeOM-IBMX or Rolipram in patient samples. The average number of 
motile cells shown in the graphs however was from three different patients of a mix 
of both IVF and ICSI. Due to the varying quality, IVF and ICSI samples are 
separated later in the study. In conclusion, PDE inhibitors 8-MeOM-IBMX and 
Rolipram increase the percent of motile cells in patient sperm samples. For this 
reason it is mainly patient samples which are used during the study. 
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Chapter 3: Investigating the effects of PDE inhibitors using different sperm 
media, PDE inhibitor concentrations and longer incubation periods 
 
3.1 Investigating the effect of PDE inhibitors using non-capacitating media 
 
3.1.1 Introduction 
 
It is known that sperm motility is effected by preparation and motility can be 
provoked and maintained by capacitating conditions (Moseley et al., 2005). As 
shown in chapter 2, PDE inhibitors have a positive effect on the percent of motile 
cells in patient sperm samples. However, the method of sperm preparation varies 
between ART clinics including the technique and media used. Media used also 
depends on which procedure, for example in Dundee’s ACU ICSI is carried out in 
non-capacitating conditions whereas IVF is carried out in sperm media and requries 
the effect of CO2 for pH equilibration and sperm capacitation. Considering the 
variation between procedures and different units it is important to determine whether 
the effect of PDE inhibitors on patient sperm motility is maintained in non-
capacitating media. Sperm samples suitable for Intra-uterine insemination (IUI) are 
also often prepared in non-capacitating media. Reasons for this include sperm for IUI 
are to be washed of the seminal plasma and not capacitated as they do this naturally 
within the female tract (Suarez and Pacey, 2006).  
 
A previous study investigated the effect of an increasing intracellular cAMP on 
calcium influx (Torres-Flores et al., 2008). This group used Papaverine, a PDE 
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inhibitor to increase the cAMP content in non-capacitated sperm. They found that the 
levels of Ca2+ induced by progesterone increased to similar levels to that found in 
capacitated sperm. With this evidence it may be suggested that the required levels of 
sAC are maintained even with a lack of HCO3- resulting in enough cAMP produced 
for sperm motility to remain high. However, it is also known that capacitating media 
contains HCO3- which is necessary for sperm capacitation and hyperactivation. 
Previous studies have carried out investigations on PDE inhibitors and human sperm 
in media supplemented with bicarbonate (Leclerc et al., 1996) or media without 
bicarbonate or albumin (Lefievre et al., 2000). A study carried out by Leclerc et al 
1996 on cAMP regulation of protein tyrosine phosphorylation on human sperm 
capacitation and motility, investigated the effect of different media on sperm. They 
made a comparison between the percent of capacitated sperm when incubated for 4 
hours in either Ham’s F-10 medium or bicarbonated supplemented Ham’s. They 
found that human sperm capacitation was only stimulated in the presence of 
bicarbonate when treated with 12-0-tetradecanoyl phorbol 13-acetate (TPA), a 
protein kinase C agonist known to induce cAMP levels. They also found that in the 
presence of IBMX, there was an increase in phosphotyrosine content, an effect that 
was potentiated by bicarbonate. Whether sperm motility increases or decreases 
depending on the media used, it is crucial that PDE inhibitors maintain their motility 
enhancing effect if they are to be used clinically. This section investigates the effect 
of PDE inhibitors on human sperm motility in non-capacitating conditions. 
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3.1.2 Materials and Methods 
 
Three patient sperm samples were prepared as described in Chapter 2 (2.2.1.2). After 
centrifugation in HEPES buffered Earle’s medium, a dilution was made to the 
required concentration of approximately 20x106/ml in this non-capacitating medium. 
Only the 40% fraction was assessed in this case. Samples were incubated with 8-
MeOM-IBMX or Rolipram as described in Chapter 2 (2.2.2). Samples were 
incubated over a period of 4 hours in the HEPES buffered Earle’s medium as this is 
roughly how long it takes for sperm to capacitate in capacitating media. T-test was 
used in statistical analysis to compare the mean of both control and treated and P 
value <0.05 was considered significant. 
 
 
3.1.3 Results 
 
There was a significant increase in the mean percent of motile cells after the addition 
of 8-MeOM-IBMX at each time point (1, 2, 3 and 4 hours incubation) in HEPES 
based non-capacitating sperm media (Figure 3.1.1). 
 
 
 
 
 
45 
Figure 3.1.1 Each bar represents the mean percent of motile cells in the 40% fraction 
of 3 different patient sperm samples at 1, 2, 3 and 4 hours incubation with or without 
the addition of 8-MeOM-IBMX in HEPES based sperm media. P<0.05 at each time 
point and is therefore statistically significant.  
 
 
There was a significant increase in the mean percent of motile cells after the addition 
of Rolipram at 1, 2, 3 and 4 hours incubation in HEPES based sperm media (Figure 
3.1.2). 
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Figure 3.1.2 Each bar represents the mean percent of motile cells in the 40% fraction 
of 3 different patient sperm samples at 1, 2, 3 and 4 hours incubation with or without 
the addition of Rolipram in HEPES based sperm media. P<0.05 at each time point 
and is statistically significant. 
 
 
3.1.4 Discussion 
 
The results shown by figures 3.1.1 and 3.1.2 are similar to the results shown in the 
previous chapter with regards to the percent of motile cells increasing after the 
addition of PDE inhibitors. Since this is consistent, the media does not impact upon 
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the effect of PDE inhibitors on sperm motility of patient samples. Sperm motility is 
generally lower in non-capacitating media compared to capacitating conditions. 
Reasons for this may include non-capacitating buffers such as HEPES, do not 
contain bicarbonate. Bicarbonate is known to change the fluidity of sperm membrane 
and directly activates sAC (Chen et al., 2000). As it induces these changes to the 
sperm membrane, the activity of sAC increases the levels of cAMP which then 
modulates the activity of PKA. Through this signalling pathway, flagellar motility is 
regulated and capacitation is induced. Notably, PDE inhibitors, which restrict the 
breakdown of cAMP, are essentially mimicking the effect of bicarbonate. The same 
can be said for phosphatase inhibitors which prolong PKA-mediated phosphorylation 
(Gadella and Harrison, 2000). Without bicarbonate in the surrounding sperm media 
however it is not known as to whether PDE inhibitors would have similar effects on 
sperm motility as they do in capacitating media. Since bicarbonate is responsible for 
sperm capacitation and is abundant in the female reproductive tract, it is for this 
reason sperm are washed in non-capacitating media prior to IUI. This allows the 
capacitating effects of bicarbonate to take place naturally in the female tract, 
preventing premature capacitation and possibly acrosome reaction. 
 
The results demonstrate that PDE inhibitors may be used clinically for procedures 
such as IUI as they maintain their positive effect on sperm motility. The remainder of 
the study was continued in capacitating conditions. Reasons for this include 
mimicking the conditions of the female tract to gain a better insight into the effects 
sperm will have when reaching the oocyte, which will be discussed later in the thesis. 
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3.2 Effects of varying incubation periods and concentrations of PDE inhibitor on 
human sperm motility 
 
3.2.1 Introduction 
 
The previous results demonstrate that PDE inhibitors maintain their effect on human 
sperm motility regardless of the preparation media and their surrounding conditions. 
The next step was to investigate the effect of the length of sperm and PDE inhibitor 
incubation time and different PDE inhibitor concentrations. 
 
As sperm swim through the female reproductive tract, it is regulated to ensure that 
the best quality sperm succeed to the sperm-oocyte interaction stage. It can take 
hours for sperm to reach the oocyte in humans (Harper et al., 1994), for which sperm 
must undergo a series of physiological changes and face multiple barriers such as 
cervical mucus. During this time, sperm must maintain their potential for fertility. 
Sperm of good motility and normal morphology are more likely to reach the ampulla 
in the fallopian tubes, (the site of fertilisation), than those of slower progression 
and/or morphologically abnormal. Enhancing the ability of sperm to swim this long 
journey could provide possibilities for subfertile men with poor quality samples. 
These include samples with slow progressing sperm which cannot swim fast and 
would presumably not last the entire journey to meet the oocyte. Experiments were 
carried out over an extended incubation period to determine whether PDE inhibitors 
can maintain their effect on human sperm. If PDE inhibitors were to be used for IUI 
it would be beneficial to know that their effects on sperm motility can be maintained 
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until the site of fertilisation. Patient and donor sperm samples were examined in this 
section since although previous results show that PDE inhibitors do not have a 
significant effect on donor sperm motility, we do not yet know the effect of these 
inhibitors over a longer time period. This may be when sperm begin to burn out in 
the female reproductive tract. It would therefore be useful to know if even good 
quality sperm from donor samples maintain their progression. The benefit of this 
would be for couples undergoing IUI.  
 
Sperm samples were also incubated with 8-MeOM-IBMX at either 100µM or 
200µM final concentrations to determine whether increasing the concentration of a 
PDE inhibitor would have more (or less) of an effect on sperm motility. Due to the 
limited amount of information regarding PDE inhibitors on human sperm motility, it 
is not known which concentration of PDE inhibitors is best for the sperm. Increasing 
PDE inhibitor concentration may have a negative or positive effect on the sperm. 
This is another factor which must be determined if the drugs were to be used 
clinically.  
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3.2.2 Materials and Methods 
 
3.2.2.1 Donor sperm preparation 
 
Three different donor sperm samples were prepared as previously described in 
Chapter 2 (2.2.1.1). As before, 99µl of sperm suspensions were placed in control and 
two treated labelled eppendorfs. 1µl PDE inhibitor 8-MeOM-IBMX at a final 
concentration of either 100µM or 200µM was then added to the treated eppendorfs. 
The mean percent of motile cells from both 40% and 80% fractions, with and without 
PDE inhibitor was assessed at 1 hour incubation periods up to 8 hours. ANOVA was 
used in statistical analysis and P value <0.05 was considered significant. 
 
 
3.2.2.2 Patient sperm preparation 
 
Three different patient sperm samples were prepared as previously described in 
Chapter 2 (2.2.1.2). As before, 99µl of sperm suspensions were then placed in 
control and two treated eppendorfs. 1µl PDE inhibitor 8-MeOM-IBMX at a final 
concentration of either 100µM or 200µM was then added to the treated eppendorfs. 
The mean percent of motile cells from only the 40% fraction in this case, with and 
without PDE inhibitor was assessed at 1 hour incubation periods up to 8 hours. 
ANOVA general linear model was used in statistical analysis and P value <0.05 was 
considered significant. 
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Rolipram was also used in this section to determine its effect over a longer 
incubation period. This was added at a final concentration of 10µM to the 40% 
fraction of three different patient samples. The mean percent of motile cells was 
assessed at 1 hour incubation periods up to 8 hours. ANOVA was used in statistical 
analysis and P value <0.05 was considered significant. 
 
 
3.2.3 Results 
 
There was no significant difference in the mean percent of motile cells in the 80% 
fraction of donor sperm using 8-MeOM-IBMX at 0.5, 1 and 2 incubation periods 
(Figure 3.2.1). However, there was a significant difference during 4, 6 and 8 hour 
incubation periods between sperm with and without 100µM 8-MeOM-IBMX 
(P<0.05). 
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Figure 3.2.1 Each bar represents the mean percent of motile cells from 80% fraction 
of three different donor samples after incubation with 8-MeOM-IBMX at a final 
concentration of 100µM between 0.5 and 8 hours.  
 
 
The same experiment was carried out using a final concentration of 200µM 8-
MeOM-IBMX on the 80% fraction of donor sperm (Figure 3.2.2). 
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Figure 3.2.2 Each bar represents the mean percent of motile cells from 80% fraction 
of three different donor samples after incubation with 8-MeOM-IBMX at a final 
concentration of 200µM between 0.5 and 8 hours. 
 
 
There was no effect on the mean percent of motile cells at 0.5, 1 and 2 hours of 
incubation when the 80% fraction of donor sperm were incubated with 8-MeOM-
IBMX at a final concentration of 200µM. However, there was a significant 
difference during 4, 6 and 8 hour incubation periods between sperm with and without 
200µM 8-MeOM-IBMX (P<0.05).  
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Increasing the final concentration of 8-MeOM-IBMX to 200µM does not seem to 
improve sperm motility of the 80% fraction of donor samples more than observed 
using 8-MeOM-IBMX at a final concentration of 100µM. Following this, the same 
experiments were carried out on the 40% fraction of donor sperm. 
 
 
Figure 3.2.3 Each bar represents the mean percent of motile cells from 40% fraction 
of three different donor samples after incubation with 8-MeOM-IBMX at a final 
concentration of 100µM between 0.5 and 8 hours. 
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There was no effect on the mean percent of motile cells at 0.5, 1 and 2 hours of 
incubation when the 40% fraction of donor sperm were incubated with 8-MeOM-
IBMX at a final concentration of 100µM. However, there was a significant 
difference during 4, 6 and 8 hour incubation periods between sperm with and without 
100µM 8-MeOM-IBMX (P<0.05)  (Figure 3.2.3). 
 
 
Figure 3.2.4 Each bar represents the mean percent of motile cells from 40% fraction 
of three different donor samples after incubation with 8-MeOM-IBMX at a final 
concentration of 200µM between 0.5 and 8 hours. 
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 There was no effect on the mean percent of motile cells at 0.5, 1 and 2 hours of 
incubation when the 40% fraction of donor sperm were incubated with 8-MeOM-
IBMX at a final concentration of 200µM. However, there was a significant 
difference during 4, 6 and 8 hour incubation periods between sperm with and without 
200µM 8-MeOM-IBMX (P<0.05) (Figure 3.2.4). 
 
Increasing the final concentration of 8-MeOM-IBMX to 200µM does not seem to 
improve sperm motility of the 40% fraction of donor samples more than observed 
using 8-MeOM-IBMX at a final concentration of 100µM. Following this, the mean 
percent of motile cells in the 40% fraction of patient samples was also investigated 
through an 8 hour incubation period after the addition of 8-MeOM-IBMX at a final 
concentration of 100µM (Figure 3.2.5). 
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Figure 3.2.5 Each bar represents the mean percent of motile cells from 40% fraction 
of three different patient sampels after incubation with 8-MeOM-IBMX at a final 
concentration of 100µM between 0.5 and 8 hours.  
 
 
There was a significant increase (P<0.05) in the mean percent of motile cells in the 
40% fraction of patient samples after the addition of 100µM 8-MeOM-IBMX which  
remained constant between 0.5 and 8 hours of incubation apart from the 2 hour 
incubation period. The next step was to investigate the effect of increasing the final 
concentration of 8-MeOM-IBMX to 200µM on the mean percent of motile sperm in 
the 40% fraction of patient sperm samples. 
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Figure 3.2.6 Each bar represents the mean percent of motile cells from 40% fraction 
of three different patient sampels after incubation with 8-MeOM-IBMX at a final 
concentration of 200µM between 0.5 and 8 hours. 
 
 
There was a significant increase (P<0.05) in the mean percent of motile cells in the 
40% fraction of patient samples after the addition of 200µM 8-MeOM-IBMX which  
remained constant between 0.5 and 8 hours of incubation apart from the 1 hour 
incubation period (Figure 3.2.6). 
 
 
 
 
59 
Increasing the final concentration of 8-MeOM-IBMX to 200µM does not seem to 
improve sperm motility of the 40% fraction of patient samples more than observed 
using 8-MeOM-IBMX at a final concentration of 100µM. Following this, an 8 hour 
incubation period was carried out using PDE-4 inhibitor Rolipram at a final 
concentration of 10 µM on the 40% fraction of patient samples to investigate the 
effect on the mean percent of motile cells (Figure 3.2.7).  
 
 
Figure 3.2.7 Each bar represents the mean percent of motile cells from 40% fraction 
of three different patient sampels after incubation with Rolipram at a final 
concentration of 10µM between 0.5 and 8 hours.  
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There was a significant increase (P<0.05) in the mean percent of motile cells in the 
40% fraction of patient samples after the addition of 10µM Rolipram which  
remained constant between 0.5 and 8 hours of incubation (Figure 3.2.7).  
 
 
3.2.4 Discussion 
 
For sperm to reach the oocyte it is essential that they can survive the journey through 
the female reproductive tract. For good quality sperm this may be a case of the 
motile count of a samples or maintaining progressive motility for a number of hours 
to ensure sperm-oocyte interaction takes place. For poor quality sperm such as 
samples from sub-fertile men, the number of motile cells in a sample may be the 
determining factor for getting to the site of fertilisation.  
 
The above results suggest as before that 8-MeOM-IBMX does not have an effect on 
the percent of motile cells in donor sperm samples (Chapter 2 2.3.1), and that 8-
MeOM-IBMX does have an effect on the percent of motile cells in patient sperm 
samples (Chapter 2 2.3.2) over a couple of hours. In addition to this, the results show 
that PDE inhibitor 8-MeOM-IBMX has an effect on patient sperm over 8 hours of 
incubation not only on patient sperm but also donor samples at longer time periods. 
This may be beneficial even for perfectly normal sperm samples in cases such as IUI 
since it can take hours for sperm to reach the oocyte and may prevent sperm burning 
out. Donor sperm for IUI procedures is commonly used as a frozen-thawed sample 
which is known to have reduced semen quality (Lim, et al 2010) due to the freeze-
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thaw process. The average success rates for donor insemination are relatively low 
with women under the age of 35 having a success rate of 15.3% in the UK in 2008 
(HFEA, 2010). If PDE inhibitors can maintain their effects on sperm motility for 
longer time periods this may increase the success rate of IUI altogether.  
 
Increasing the final concentration of 8-MeOM-IBMX to 200µM had no further effect 
when compared to the effect of using 100µM (as used in Chapter 2) on either donor 
or patient sperm over any time period. This suggests that 100µM may be the optimal 
concentration for increasing human sperm motility. However, such limited 
information is available on the effect of PDEs on human sperm that investigating 
various concentrations may be a consideration of further research. It is therefore 
unknown as to what the optimal concentration of any PDE inhibitor is on human 
sperm with regards to improving motility and function. It is also unknown as to 
whether any damage may be caused by increasing PDE inhibitor concentration on 
the sperm cell. The results however suggest that although increasing the 
concentration of 8-MeOM-IBMX does not improve sperm motility, it does not 
appear to have any negative effect on the percent of motile sperm within a sample. 
This may be a small amount of information but may be valuable in the investigation 
of PDE inhibitors on human sperm.  
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3.3 The effect of combining PDE inhibitors on human sperm motility 
 
3.3.1 Introduction 
 
Previous studies carried out using PDE inhibitors on sperm have investigated the 
inhibitors individually. In other words, concentrating on the effects of one PDE 
inhibitor at a time on sperm. Reasons for this may include the fact that generally little 
is known about the effect of PDE inhibitors on human sperm and so a more thorough 
investigation is carried out using one inhibitor. Although studies have shown PDE 
inhibitors have a strong positive effect on human sperm motility, further information 
is yet to be determined such as varying concentrations or extended incubation 
periods as discussed previously. Since this study suggests that individual PDE 
inhibitors increase the percent of motile cells in patient samples, it is important to 
determine whether this effect can be further advanced (or if it negatively effects 
sperm) simply by incubating patient sperm with more than one inhibitor. No study to 
date has examined the effect of combinding more than one PDE inhibitor on human 
sperm motility. In this section, the 40% fraction of patient sperm samples were 
incubated with both 8-MeOM-IBMX and Rolipram (as used in previous sections) in 
order to determine the effect of combining PDE inhibitors on the percent of motile 
cells of patient sperm samples.  
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3.3.2 Materials and Methods 
 
Three different patient sperm samples were prepared as described previously 
(Chapter 2 2.2.1.2). Only the 40% fraction was examined in this section. The sperm 
suspension was assessed at 0.5, 1 and 2 hour incubation periods with the addition of 
both 8-MeOM-IBMX and Rolipram at final concentrations of 100µM and 10µM 
respectively. ANOVA general linear model was used in statistical analysis and P 
value <0.05 was considered significant.    
 
 
3.3.3 Results 
 
The effect of adding 8-MeOM-IBMX or Rolipram individually to the 40% fraction 
of patient sperm samples significantly (P<0.05) increased the mean percent of motile 
sperm at the 0.5, 1 and 2 hour incubation periods (Figure 3.3.1) as demonstrated in 
previous sections. The combined effect of both 8-MeOM-IBMX and Rolipram had a 
significant (P<0.05) effect by increasing the mean percent of motile cells of the 40% 
fraction of patient sperm at 0.5, 1 and 2 hour incubation periods.   
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Figure 3.3.1. Graph demonstrating the mean percent of motile cells when the 40% 
fraction of three different patient sperm samples are incubated with either 8-MeOM-
IBMX, Rolipram and both at 0.5, 1 and 2 hour incubation periods.  
 
 
3.3.4 Discussion 
 
The results show consistency with previous sections in that using 8-MeOM-IBMX or 
Rolipram individually has a significant positive effect on the motility of patient 
sperm samples. The results of combining both 8-MeOM-IBMX and Rolipram also 
significantly increases the percent of motile sperm in patient samples. This increase 
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was greater than the effect of Rolipram alone. This suggests that the use of two 
inhibitors rather than one has a positive effect on sperm motility, and more 
importantly this does not seem to have a negative effect on human sperm motility.  
However, the effect of both inhibitors on the percent of motile cells combined is less 
than that of 8-MeOM-IBMX. This suggests the opposite in that the use of both 
inhibitors may be an overload for the sperm cell in terms of a possible build up of the 
levels of cAMP, essentially causing the sperm to burn out. If so, this may prevent the 
use of combining PDE inhibitors clinically (or at least certain PDE inhibitors) since 
what appears to be a negative effect on patient sperm. More investigation on the 
effect of combining PDE inhibitors on sperm motiltiy is required using different PDE 
inhibitors on a larger population of sub-fertile patients. As before, these results may 
be skewed by the small numbers examined and the variation between samples. 
However, in conclusion to these results it would appear as though a combination of 
PDE inhibitors does improve sperm motility, although not to the extent of one 
inhibitor alone.  
 
 
3.4 The effect of washing sperm after PDE inhibitor incubation  
 
3.4.1 Introduction 
 
Clinical sperm preparation consists of ‘washing’ the sperm in gamete buffer to 
remove any remaining PureSperm® silica particles after gradient centrifugation. 
Washing sperm also gets rid of any dead or slow moving sperm along with these 
 
 
 
 
66 
addition chemicals. This is done to remove what may impair fertilisation. If PDE 
inhibitors leave a residue in the media surrounding the sperm, it may be crucial that 
PDE inhibitors are added before a wash if PDE inhibitors were to be used in a 
clinical setting. This would wash patient sperm from their surrounding media to 
eliminate the chance of PDE inhibitors being transmitted into the uterus in such cases 
as preparation for IUI. Preparation for IVF insemination would also require the PDE 
inhibitor surrounding media to be washed as this media would be inseminated along 
with patient sperm into the insemination dish containing oocytes. Previous studies 
investigating the effects of PDE inhibition on human sperm motility have not washed 
the sperm suspensions after adding PDE inhibitors (Lefievre et al., 2002). Reasons 
for this may include the fact that generally little is known about the effect of PDE 
inhibitors on sperm and we are not yet at the stage of investigating alternatives in 
sperm preparation, such as the effect of adding a further wash step. However it is 
important when investigating the effect of PDE inhibitors on human sperm to gain as 
much knowledge as possible and determine whether the positive effects of PDE 
inhibitors on patient sperm motility are maintained.  
 
 
3.4.2 Materials and Methods  
 
Three different patient sperm samples were collected and prepared as described 
previously (Chapter 2 2.2.1.2). After the addition of PDE inhibitor 8-MeOM-IBMX 
or Rolipram at final concentrations of 100µM and 10µM respectively, the sperm 
suspensions were incubated for 1 hour at 37°C with 6% CO2. These suspensions 
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were then placed in 5ml pre-equilibrated STF medium and density gradient 
centrifugated again for 10 minutes at 500g. Following this extra wash step, the media 
was taken off as far as the pellet and the pellet was suspended in pre-equilibrated 
STF to a final concentration of approximately 20x106/ml for assessment using 
CASA. T-test was used in statistical analysis and P value <0.05 was considered 
significant. 
 
 
3.4.3 Results 
 
The results demonstrate that there is no significant difference (P>0.05) between the 
mean percent of motile cells from the 40% fraction of patient sperm following 1 hour 
incubation of either 8-MeOM-IBMX or Rolipram following an additional wash step 
(Figure 3.4.1). The percent of motile cells for samples which had an additional wash 
step were high and similar to that of samples without an extra wash. 
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Figure 3.4.1 Graph comparing the mean percent of motile cells between unwashed 
and washed sperm from the 40% fractions of three different patient semen samples 
after incubation with 8-MeOM-IBMX or Rolipram at final concentrations of 100µM 
and 10µM respectively for 1 hour.  
 
 
3.4.4 Discussion 
 
The resuts suggest that introducing an additional wash stage in the preparation of 
patient sperm samples when using PDE inhibitors would have no additional effect 
(positive or negative) on patient sperm. The benefit of this is knowing that if it is a 
requirement that PDE inhibitors must be washed from the surrounding media, they 
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maintain their positive effect on patient sperm motility. This would also be 
convenient during patient sperm preparation as PDE inhibitors may be added during 
the sperm preparation procedure which could save time in an embryology laboratory 
prior to insemination. Since the results demonstrate that PDE inhibitors maintain 
their effects after the removal of any unwanted PDE inhibitor from the surrounding 
media after 1 hour incubation, this almost ensures the PDE inhibitor remains within 
the cell.  
 
One of the most important aspects of this result is that washing sperm after PDE 
inhibitor incubation has no negative effect on sperm motility. Experiments carried 
out previously in this study have mainly demonstrated a positive relationship 
between PDE inhibitors and sperm motility. However, due to the limited amount of 
information on PDE inhibitors in human sperm, little is known about the effect they 
may have on any functional and physiological damage on sperm. It would appear 
thus far that PDE inhibitors do not have a negative effect on sperm however this has 
only been concluded through studies regarding the maintainence of motility (Fisch et 
al., 1998). Sperm damage may include induced change to the acrosomal status of a 
sperm head or induced sperm DNA damage. This may not only affect the ability of 
sperm to bind to the oocyte, but also fertilisation results. If adding PDE inhibitors to 
increase the fertilisation potential of sperm proves to have a negative effect on sperm 
in any way, this will prohibit the use of the inhibitors clinically. The next section 
explores the effects of PDE inhibitors on sperm function and potentially the 
fertilising ability of human sperm.  
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Chapter 4: Sperm physiology and PDE inhibitors 
 
4.1 Acrosome Reaction 
 
4.1.1 Introduction 
 
The acrosome of mammalian sperm is a membranous exocytotic sac containing 
many kinds of hydrolytic enzymes (Harper et al., 2008). It plays a crucial role during 
sperm-oocyte interaction. Freshly ejaculated sperm must acquire the ability to 
fertilise an oocyte which is done by a series of changes known as capacitation. 
Capacitation involves changes such as modifications to plasma membrane lipid 
composition and the acquisition of hyperactivated motility (Lishko et al., 2011). The 
acrosome reaction can only happen in capacitated sperm, enabling them to eventually 
fuse with the oocyte. Mitchell et al, 2007 demonstrated that capacitation is associated 
with an increase in sperm-zona pellucida binding. This study added zona-pellucida 
from human oocytes to sperm from capacitating or non-capacitating conditions and 
counted the number of sperm bound using phase contrast and fluorescence 
microscopy. They showed significantly more sperm were able to bind to zona-
pellucida after allowing them to capacitate. This demonstrates the importance of 
capacitation during this step in fertilisation. During the acrosome reaction, acrosomal 
contents such as hydrolytic enzymes and acrosomal antigens are gradually realised in 
intermediate stages as sperm develop the potential to fuse to the surface of the 
oocyte. As the outer acrosome membrane of the sperm fuses with the oocyte the 
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acrosomal contents along with the inner acrosomal membrane are exposed to the 
extracellular medium (Bhandari et al., 2010).  
There is debate as to when the acrosome reaction actually takes place during sperm-
oocyte interaction and the consequences this may have on the ability of sperm to 
fertilise. For instance, it has been suggested that human sperm that have undergone 
premature acrosome reaction cannot fertilise (Liu and Baker, 1990). However, it is 
also suggested that acrosome reacted sperm within the vicinity of the oocyte are 
capable of fertilisation (Morales et al., 1989). Other studies have also suggested that 
in various species such as mice, sperm can only initiate binding to the zona pellucida 
if acrosome intact (Saling and Storey, 1979; Florman and Storey, 1982; Bleil and 
Wassarman, 1983). However, recent studies have shown that most fertilising sperm 
undergo the acrosome reaction before reaching the zona-pellucida (Jin et al., 2011). 
Using fluorescence microscopy, this study evaluated the acrosome reaction during 
sperm-oocyte interaction in mice sperm and oocytes, providing further debate on the 
stage of sperm acrosome reaction and the need for a better understanding of sperm 
physiology during fertilisation. However, it is important to remember that the 
physiology of sperm-oocyte interaction may be species specific and what applies to 
mice may not be the same for human gametes. 
 
The acrosome reaction plays a key role in the sperm-oocyte interaction (Cross et al., 
1988). Recent studies have explored various factors as to what promotes this 
physiological change. It has been suggested that human zona pellucida can induce 
acrosomal exocytosis (Ganguly et al., 2010). The human zona pellucida is an 
extracellular glycoprotein coat which is composed of four main glycoproteins. It acts 
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as an agonist for acrosomal exocytosis of the sperm head and plays an important role 
in the protection of the oocyte in maintaining cytoplasmic contents and preventing 
polyspermy. The precise function of each of the four glycoproteins (ZP1, ZP2, ZP3 
and ZP4) in human zona pellucida has been a topic of great interest. It has previously 
been demonstrated that in human oocytes, ZP3 and ZP4 binds to capacitated 
acrosome intact sperm and induces the acrosome reaction (Chiu et al., 2008). More 
recently ZP1 has also been shown to bind to capacitated acrosome intact sperm, 
inducing the acrosome reaction (Ganguly et al., 2010). It has previously been shown 
however that ZP2 binds to the acrosome and does not induce the acrosomal 
exocytosis in capacitated human sperm (Chakravarty et al., 2008). Acrosomal 
exocytosis in human sperm may be a combined effect of all three zona pellucida 
glycoproteins binding to sperm and inducting the acrosome reaction. Further studies 
are required to determine the exact role of the zona pellucida on the acrosome status 
of human sperm and when exactly the acrosome reaction should take place in order 
to achieve fertilisation. 
 
It has previously been suggested that premature acrosome reaction may counteract 
the effects of the ability of sperm to fertilise an oocyte (Tesarik et al., 1992). 
Promotion of the acrosome reaction may therefore not be beneficial in improving 
fertilisation rates. Whilst it is important that sperm undergo this physiological 
change, it is also important that PDE inhibitors do not promote the acrosome reaction 
due to the chance of it being detrimental to sperm-oocyte interaction. There has 
previously been correlation between PDE inhibitors and the acrosome reaction. Fisch 
et al 1998 demonstrated a significant stimulating effect on sperm acrosome with the 
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use of PDE-1 inhibitor 8-MeOM-IBMX. This would make sense since PDE-1 is 
predominantly found in the sperm head (Lefievre et al., 2002). In contrast, PDE-4 
inhibitor Rolipram provoked a significant improvement in sperm motility yet did not 
affect the acrosome. However, whilst these results look clinically positive, studies 
have demonstrated a negative effect on the use of PDE inhibitors on sperm acrosome 
and in turn sperm function. Glenn et al 2007 demonstrated the PDE-5 inhibitor 
Sildenafil induced a significant increase in the percent of acrosome reacted sperm. In 
contrast, Lefièvre et al 2000 reported that Sildenafil increases sperm motility, 
capacitation, protein tyrosine phosphorylation but not the acrosome reaction. Due to 
constant debate, the acrosome reaction must be evaluated to determine whether PDE 
inhibitors have any effect on the acrosomal status of human sperm cells. Even though 
this subject is still controversial, if it is clear that PDE inhibitors induce the acrosome 
reaction they would not be used clinically due to these unwanted effects. PDE 
inhibitors 8-MeOM-IBMX and Rolipram were used in this section as these are the 
inhibitors which have shown so far in this study to have the greatest effect on sperm 
motility. If these inhibitors provoke the acrosome reaction they would not be used 
clinically due to the risk of premature acrosome reaction negatively influencing 
fertilisation success. 
 
 
4.1.2 Materials and Methods 
 
The 80% fraction of three different donor samples was used in this section. They 
were collected and prepared as previously described (Chapter 2 2.2.1.1). Following 
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sperm preparation the samples were suspended at a concentration of approximately 
10x106M/ml in 0.5ml pre-equilibrated STF. The sperm suspensions were incubated 
at 37°C, 6% CO2 for 3 hours to allow capacitation. Three 1.5ml eppendorfs were 
prepared of control, positive control and treated. After incubation, 0.5ml suspended 
sample was added to each eppendorf. For the control, 0.5µl DMSO was added giving 
0.1% DMSO (only if PDE inhibitor used was diluted in DMSO). For the positive 
control, 2.5µl of Ca2+ ionophore A23187 was added at a final concentration of 10µM 
(Fisch., et al 1998). For the ‘treated’ sample, 5µl of either 8-MeOM-IBMX or 
Rolipram was added (PDE inhibitors diluted to required final concentration 
beforehand). The 3 eppendorfs were then incubated at 37°C at 6% CO2 for 60 
minutes. 2.5µl of propidium iodide was then added to each eppendorf at a final 
concentration of 12µM and left for 15 minutes at 37°C. The samples were then 
washed by centrifugation for 10 minutes at 500g and the supernatant discarded. The 
pellet was suspended in 200µl STF before transferring to slides. 20µl of the sperm 
suspension was transferred from each eppendorf to poly-L-lysine coated slides and 
left for 30 minutes to air dry. To make the sperm cells permeable they were 
immersed in 100% methanol for 1 minute at room temperature and dried 
immediately on a heated stage to rapidly evaporate the methanol. 25µl fluorescein 
isothiocyanate-conjugated Pisum sativum agglutinin (FITC-PSA) was then added to 
each slide at a concentration of 50µg/ml (Fisch., et al 1998). Slides were incubated 
for 1 hour in a moisture chamber at 37°C before being washed in a gentle stream of 
water for 2-3 minutes. Slides were then mounted and left to air dry in the dark at 
room temperature for at least 30 minutes before being evaluated. Evaluation was 
carried out by counting 200 cells per slide in duplicate. Cells were then viewed under 
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a fluorescence microscope (40x objective) and counted as acrosome intact live cells, 
acrosome reacted live cells, acrosome intact dead cells and acrosome reacted dead 
cells (Cross, 1986). Data on the sperm acrosome reaction test is presented as a mean 
percent from the proportion of living sperm. T-test was used in statistical analysis 
and P value <0.05 was considered significant. 
 
 
4.1.3 Results 
 
The results shown are taken from the live cell count only. The comparison between 
the percent of cells acrosome intact and acrosome reacted is clear between the 
negative and positive control (Figure 4.1). The average percentage of acrosome 
reacted sperm in the negative control was 11.75% (± 1.3% SEM) whereas the 
positive control treated with Ca2+ ionophore A23187 showed 45% (± 7.9% SEM) 
(Table 1). The results are statistically significant (P<0.05). Rolipram at a final 
concentration of 10µM did not have a significant effect on the acrosome reaction of 
sperm. When compared with the negative control the difference in the percent of 
acrosome reacted sperm was 0.5% (± 1.3% SEM) (P>0.05) thus showing no clear 
stimulating effects. 8-MeOM-IBMX at 100µM however showed a small but 
significant result. When compared with the negative control, the difference in the 
percent of acrosome reacted sperm was 3.08% (± 0.58% SEM) (P=0.042).  
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Figure 4.1 Graph representing the mean percent of live cells acrosome intact and 
reacted from the 80% fraction of three different donor sperm samples after 1 hour 
incubation with either 8-MeOM-IBMX or Rolipram at final concentration of 100µM 
and 10µM respectively. 
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Compound PDE Inhibited % Reacted cells 
(mean ± SEM) 
P value 
Control vs. treated 
Negative control 
 (0.1% DMSO) 
- 11.75 ± 1.3 - 
Positive control 
(10µM A23187) 
- 45 ± 7.9 - 
8-MeOM-IBMX 
(100µM) 
PDE-1 8.67 ± 0.72 P=0.042 
Rolipram  
(10µM) 
PDE-4 11.25 ± 2.61 P=0.58 
 
Table 4.1 Table demonstrates the effect of 8-MeOM-IBMX and Rolipram on the 
acrosomal status of human sperm.  
 
 
4.1.4 Discussion 
 
This study was carried out in order to determine whether or not PDE inhibitors have 
an effect on the acrosomal status of human sperm. The results gained suggested that 
PDE inhibitors 8-MeOM-IBMX and Rolipram do not induce the acrosome reaction 
in human sperm compared to what occurs naturally. It has long been thought that 
sperm must acrosome react within the vicinity of the oocyte in order to go on and 
penetrate the oocyte. The site at which the acrosome reaction takes place is still an 
on-going debate and the stability of sperm after they have acrosome reacted is 
unknown. However, it is known that sperm must undergo the acrosome reaction in 
order to penetrate and fertilise the oocyte.  
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Previous studies have observed an increase in acrosome reacted sperm when 
incubated with PDE inhibitors suggesting the inhibitors are involved in promoting 
this reaction. Reasons for this may be due to the use of non-selective PDE inhibitors 
such at PTX. PDE inhibitors such as PTX have been used to stimulate sperm motility 
(Yovich et al., 1990). Tasdemir et al 1993 used PTX to evaluate any possible effects 
on sperm acrosome reaction. They found that PTX did induce the acrosome reaction 
significantly in patient samples. However, they also found a positive relationship 
between PTX treated sperm and fertilisation rates. Other reasons for previous 
correlation between PDE inhibitors and acrosome reaction are the concentration of 
non-selective PDE inhibitors used. PDE inhibitor concentrations previously used to 
achieve an increase in human sperm motility have been shown to be accompanied by 
an increase in the acrosome reaction. Fisch et al used PDE-4 type inhibitor Rolipram 
at 10µM which showed no effect on the number of acrosome reacted sperm 
compared to the non selective IBMX used at 100µM which seemed to significantly 
induce the acrosome reaction.  
 
It is important that the acrosome reaction is not initiated until the sperm are in the 
vicinity of the oocyte (Tesarik, 1989). This may not be crucial during IVF since 
sperm are placed in the vicinity of the oocyte. However, for IUI this may be what 
determines fertilisation outcome as sperm have far to travel before reaching the 
oocyte. Even though this subject is still controversial, it is important that PDE 
inhibitors do not have any negative effects on sperm function. The purpose of using 
PDE inhibitors is to improve the quality of sperm from infertile patients, in turn 
increasing the fertilisation potential of these couples. It is therefore important that 
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sperm are both morphologically and physiologically sound to function well in order 
to fertilise the oocyte. 
 
Some sperm infertility features however are not as apparent as the presence or 
absence of an acrosome. Sperm have underlying physiological issues, some of which 
include DNA damage. Detection of DNA damage is beyond that of a routine semen 
analysis but the ability to do so allows identification of one of the most important 
fertilisation determinants. It is suggested that sperm cell DNA damage may be 
caused or inherited. It is therefore important that no damage is caused to sperm DNA 
with the use of PDE inhibitors.    
 
 
4.2 Tunel Assay 
 
4.2.1 Introduction 
 
An important determinant of male infertility is DNA damage (Bungum et al., 2007). 
The sperm from some infertile men have structural and functional defects (Liu and 
Baker 1994). These defects include DNA fragmentation which frequently affects 
sperm by either hindering or preventing fertilisation. While sperm appear motile and 
morphologically normal, they may be genetically abnormal. The mechanisms of 
DNA damage include apoptosis, oxidative stress and defective chromatin packing. In 
some cases these abnormalities may be caused by environmental factors such as 
exposure to chemical and/or physical agents (Friedler, 1996). This can alter the 
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genome at the chromosomal or DNA level leading to abnormalities in the 
nucleoprotein content or DNA strand breaks. It has also been suggested that sperm 
DNA damage is inherited since fragmentation of DNA is associated with structural 
chromosomal abnormalities (Perrin et al., 2011). Sperm with DNA damage do not 
have the capacity for fertilisation. It has been demonstrated that with couples 
undergoing IUI, none of the semen samples with >12% sperm DNA fragmentation 
resulted in pregnancy (Duran et al., 2002). If DNA damaged sperm were to be 
injected into the oocyte, this may also have serious consequences on the offspring 
(Ahmadi and Ng, 1999).  
 
The TUNEL assay was first developed in the 1990s (Muratori et al., 2010) and first 
applied to human sperm in 1993 (Gorczyca et al., 1993). Problems with this 
technique include the heterogeneity of sperm DNA fragmentation. For example 
freshly ejaculated semen samples from groups of similar infertile subjects can vary 
from 2.4% (n=29) to 39.8% (n=66) DNA fragmentation (Younglai et al., 2001; 
Domínguez-Fandos et al., 2007). Due to unreliable results and lack of 
standardisation, male fertility status is difficult to predict using this technique. 
However, conflicting results suggest that the diagnostic and prognostic value of 
sperm DNA fragmentation has not been concluded and therefore with an established 
procedure, results may be precise (Muratori et al., 2010). The TUNEL assay is in fact 
used today for DNA fragmentation evaluation of sperm. Piasecka et al 2007 assessed 
the genomic integrity of asthenozoospermia patients in relation to their fertilisation 
potential. They discovered that the proportion of TUNEL-positive cells (those with 
DNA fragmentation) was significantly higher in the sperm of those patients with 
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lower motility (n=40). They also found a correlation between TUNEL-positive cells 
and other factors such as immature sperm, mid-piece abnormalities and ultra 
structural chromatin. Other studies such as Chiamchanya et al 2010 used the TUNEL 
assay to determine the percent of DNA damage after various density gradient 
centrifugations, revealing PureSperm® as yielding the best motility and the lowest 
percentage of protamine deficiency. These abnormalities can therefore be evaluated 
using the TUNEL assay and may help select sperm which are actually healthy and 
eliminate those with underlying abnormalities. 
 
It is therefore important to determine the nature of PDE inhibitors and if they have a 
negative effect on the DNA component of sperm. If there is a toxic effect and DNA 
damage is induced with the addition of PDE inhibitors then it is important that these 
drugs are not used since they will not only affect fertilisation rates but will most 
likely be harmful to the patient and any resulting offspring.  
 
 
4.2.2 Materials and Methods 
 
The 80% fraction of three different donor samples was used in this section. They 
were collected and prepared as previously described (Chapter 2 2.2.1.1). After sperm 
preparation, samples were suspended in 0.5ml HEPES based media at a sperm 
concentration of approximately 1x107M/ml. 8-MeOM-IBMX or Rolipram was added 
at final concentrations of 100µM or 10µM respectively and left at room temperature 
for 1 hour. Poly-L-lysine slides were prepared of negative control, positive control, 
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non-treated and treated. 50µl of the samples were placed onto the slides and smeared 
with a cover slip. The slides were left to air dry for 3 hours at room temperature. 
Once dry, a circle was drawn around the sample using a wax pen. The sample was 
then fixed in 100µl 4% Paraformaldehyde for 15 minutes. The slides were then 
washed in PBS wash bath for 15 minutes. Solution of proteinase K and Tris buffer (1 
in 100 dilution) was made up and 50µl placed on slide. This was left for 5 minutes at 
room temperature and then washed in PBS. 50µl DNase1 was then place on positive 
control whilst 100µl DNase1 solution placed on all other slides. All slides were left 
for 20 minutes at room temperature and then washed in PBS. 100µl of a solution 
containing TdT and dH20 (1 in 5 dilution) was added to each slide and left at 20 
minutes room temperature. 60µl of a solution containing Reaction Mix and TdT 
Enzyme were added to each slide besides the negative control, to which 60µl 
Reaction Mix alone was added. Slides were covered in parafilm and placed in 
moisture chambers for 1-1.5 hours at 37°C. Parafilm was then taken off and the 
slides were washed in PBS for 1 minute. Slides were mounted using mounting media 
with cover slips. Mounted samples were stored at 4°C in the dark. T-test was used in 
statistical analysis and P value <0.05 was considered significant. 
 
 
4.2.3 Results 
 
Results from the negative and positive controls are not recorded here. The negative 
control which should have an amount of DNA damage natural to the sample since it 
did not have the TdT enzyme added to it had 0.67 ± 0.08% DNA damaged cells. 
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There was a significant difference compared to the positive control carried out by the 
DNase1 enzyme which showed 87.04 ± 3.4% DNA damaged cells. The difference 
between the negative and positive controls is 86.38 ± 3.32% and is therefore 
statistically significant (P<0.05).  
 
 
 
Figure 4.2 Graph represents the mean percent of cells with DNA damage from the 
80% fraction of three different donor sperm samples. A comparison between non 
treated and PDE inhibitor treated samples.  
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There was no significant difference (P>0.05) in the mean percent of DNA damaged 
cells between the control and either 8-MeOM-IBMX or Rolipram treated sperm of 
the 80% fraction from donor samples (figure 4.2).   
 
 
4.2.4 Discussion 
 
Human sperm DNA damage is a prognostic factor of male infertility and is 
increasingly being recognised as a tool in predicting embryo development. 
Conventional parameters of semen analysis do not take sufficient information into 
account for a complete evaluation of a couples reproductive potential. DNA damage 
testing helps to detect defects in sperm quality. Today this has a particular 
importance due to the growing concern regarding the transmission of genetic 
diseases. The process of natural selection is bypassed with the use of ICSI allowing 
DNA damaged sperm to fertilise oocytes. Factors that impact upon the DNA 
integrity of a sperm cell may have consequences for any resulting embryo, blastocyst 
or even child. These results clearly demonstrate that PDE inhibitors do not have a 
negative effect on sperm DNA. Causes of DNA damage in sperm include abnormal 
chromatin packaging, reactive oxygen species and apoptosis (Shamsi et al., 2008). It 
is therefore clinically beneficial that PDE inhibitors do not fall into this category. 
However, these experiments were carried out on relatively low samples numbers and 
require a much larger population to gain a more reliable result. The TUNEL assay 
itself is also not a reliable test due to previous reported unreliable results and requires 
standardisation. It would also be useful to carry out further investigation on patient 
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sperm samples since sub-fertile men appear to be the target population for the use of 
PDEs. 
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Chapter 5: Further investigation on the effect of PDE inhibitors on human 
sperm motility 
 
5.1 Introduction 
 
It is surprising that even though studies have been carried out on human sperm , 
including sub-fertile patient samples, still nothing has been done to fully investigate 
the potential of PDE inhibitors. In this chapter, three PDE type specific inhibitors 
have been chosen to investigate the effect of PDE inhibitors in more depth than what 
has previously been carried out. One PDE inhibitor Milrinone, which is selective to 
PDE-3 already located in human sperm, is reported to have no effect on sperm 
motility, (Lefievre et al., 2002) another Papaverine which has an effect on human 
sperm motility yet has not been located in human sperm and lastly BRL which has 
never been studied in human or animal sperm. There is limited information available 
on these three inhibitors which are investigated in this section. It is due to ths limited 
knowledge that these three PDE inhibitors was chosen. These findings may produce 
novel results, whether they have a positive effect on sperm motility or not.   
 
PDE-3A (an isoform of PDE-3) has been located in the postacrosomal segment of 
human sperm head (Lefievre et al., 2002). This study investigated the cAMP content 
of human sperm using Milrinone. The level of cAMP increased with the use of 
Milrinone at 50µM however this did not affect sperm functions such as capacitation, 
protein phosphorylation and motility when compared to IBMX as a positive control. 
Nevertheless, both localization and inhibition confirmed the presence of PDE-3 in 
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human sperm and also confirmed Milrinone as a PDE-3 specific inhibitor. In 
contrast, Papaverine, an inhibitor of PDE-10 has been shown to have a significant 
effect on human sperm function yet has never been localized. Torres-Flores et al 
2008 examined the effect of exposing non capacitated human sperm to Papaverine. 
They found that calcium levels increased to levels close to that of capacitated sperm. 
They also found a greater effect on sperm calcium levels using Papaverine than PTX, 
a widely used PDE inhibitor for sperm motility enhancement. Since it has long been 
known that calcium is an important regulator of sperm motility, (Tash and Means, 
1983) the increase caused by Papaverine suggests that this PDE inhibitor may also 
regulate sperm motility.  
 
Little has been done to investigate the effects of PDE inhibitors in human sperm 
particularly with the knowledge that there is a correlation between PDE inhibition 
and sperm motility enhancement. These inhibitors have been chosen on that basis for 
further investigation along with BRL, an inhibitor of PDE-7 which has never before 
been studied in sperm. 
 
 
5.2 Materials and Methods 
 
The 40% fraction of three patient sperm samples was used in this study. Samples 
were collected and prepared as described previously (Chapter 2 2.2.1.2). PDE 
inhibitors Milrinone, BRL and Papaverine were used at final concentrations of 
50µM, 100µM and 100µM respectively. Sperm suspensions were incubated for 0.5, 
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1 and 2 hours at 37°C with 6% CO2. The mean percent of sperm motility and 
progressively motile cells were assessed using CASA. ANOVA was used in 
statistical analysis and P value <0.05 was considered significant. 
 
 
5.3 Results 
 
The results demonstrate a significant (P<0.05) increase in the mean percent of motile 
cells after incubation with each of the PDE inhibitors at 0.5, 1 and 2 hour incubation 
periods. Samples incubated with Milrinone showed an increase particulary at 1 hour 
with the control having an average percent motility of 42.2% ± 10.6 whilst the 
treated was 66.1% ± 8.7 (P<0.05) (Figure 5.1). Similarly BRL had a significant 
effect on the 40% fraction of patient sperm. The control had an average motility of 
42.2% ± 10.6 compared to the treated which had 71.3% ± 10.0 (P<0.05) at 1 hour 
incubation period (Figure 5.3). Papaverine also demonstrated a significant result 
when added to the 40% fraction of patient samples. The average motility of the 
control was 42.2% ± 10.6 compared to the treated samples which was 65.8% ± 12.3 
(P<0.05) at 1 hour incubation period (Figure 5.5). The average percent of 
progressively motile cells was significantly higher (P<0.05) throughout 0.5, 1 and 2 
hours for Milrinone, BRL and Papaverine (Figures 5.2, 5.4 and 5.6). 
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Figure 5.1 Each bar represents the mean percent of motile cells with or without the 
addition of Milrinone on the 40% of three different patient samples at 0.5, 1 and 2 
hour incubation periods. 
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Figure 5.2 Each bar represents the mean percent of progressively motile cells with or 
without the addition of Milrinone on the 40% of three different patient samples at 
0.5, 1 and 2 hour incubation periods. 
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Figure 5.3 Each bar represents the mean percent of motile cells with or without the 
addition of BRL on the 40% of three different patient samples at 0.5, 1 and 2 hour 
incubation periods.  
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Figure 5.4 Each bar represents the mean percent of progressively motile cells with or 
without the addition of BRL on the 40% of three different patient samples at 0.5, 1 
and 2 hour incubation periods. 
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Figure 5.5 Each bar represents the mean percent of motile cells with or without the 
addition of Papaverine on the 40% of three different patient samples at 0.5, 1 and 2 
hour incubation periods.  
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Figure 5.6 Each bar represents the mean percent of progressively motile cells with or 
without the addition of Papaverine on the 40% of three different patient samples at 
0.5, 1 and 2 hour incubation periods. 
 
 
Table 5.1 gives a comparison of the effects of different PDE inhibitors (including 
those used in previous sections) on human sperm motility. This is demonstrated after 
1 hour sperm-PDE inhibitor incubation as this appears to be when PDE inhibitors 
have the greatest effect on sperm motility. The inhibitor showing the greatest effect 
on the 40% fraction of patient sperm samples is PDE-7 type specific BRL (P<0.05). 
However, all five of the PDE inhibitors investigated have shown a significant 
increase in the mean percent of motile sperm cells with the 40% fraction of a patient 
population.  
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PDE Inhibitor PDE 
Inhibited 
Sample Percent 
motile 
Mean ± SEM 
P-value 
8-MeOM-
IBMX 
PDE-1 C 
T 
Difference 
16.5 ± 9.0 
32.6 ± 13.4 
16.1 ± 4.4 
0.036 
Rolipram PDE-4 C 
T 
Difference 
28.8 ± 11.3 
45.6 ± 9.9 
16.8 ± 1.4 
0.02 
Milrinone PDE-3 C 
T 
Difference 
42.2 ± 10.6 
66.1 ± 8.8 
23.9 ± 1.8 
0.008 
BRL PDE-7 C 
T 
Difference 
42.2 ± 10.6 
71.3 ± 10.0 
29.1 ± 0.6 
0.0004 
Papaverine PDE-10 C 
T 
Difference 
42.2 ± 10.6 
65.8 ± 12.3 
23.6 ± 1.7 
0.005 
 
Table 5.1 A comparison of the effects of various PDE inhibitors on sperm motility of 
the 40% fraction of three different patient sperm samples after 1 hour incubation.  
 
 
These results demonstrate the consistency of a significant difference between the 
percent of motile cells of patient sperm with or without PDE inhibitors. This is 
demonstrated particularly 1 hour after the addition of BRL. Due to these results, a 
wash step was carried out using BRL on the 40% fraction of three different patient 
samples. Samples were prepared as previously described (Chapter 3 3.4.2) and BRL 
was added at a final concentration of 100µM. This was done to determine whether 
BRL can maintain the positive effects demonstrated after 1 hour incubation even 
after an additional wash step. T-test was used in statistical analysis and P<0.05 was 
considered significant. 
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Figure 5.7 Graph demonstrates the mean percent of motile cells in the 40% fraction 
of three different patient sperm samples with or without the addition BRL after 1 
hour incubation with or without further density centrifugation.  
 
 
There was no significant difference in the mean percent of motile cells incubated for 
1 hour with BRL with or without an additional wash step (P>0.05).  
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5.4 Discussion 
 
The results demonstrate a significant increase in the percent of motile cells in patient 
sperm samples using Milrinone, BRL or Papaverine.  
 
Milrinone has been previously studied in the past with regards to the percent of 
hyperactivated and capacitated cells and was shown to have no effect on sperm 
functions (Lefievre et al., 2002). The results in this study however suggest that 
Milrinone increases the percent of motile sperm in patient samples. However, the 
samples used in the study by Lefievre et al 2002 were carried out on healthy 
volunteers unlike the results of this study which are based on sub-fertile patient 
samples. As discussed in other chapters, it may be that the motility from samples of 
healthy donors cannot be enhanced unlike sperm from patient samples where there is 
room for improvement. This suggests a target population of sub-fertile men.   
 
Papaverine also demonstrated a significant increase in the percent of motile sperm of 
patient samples in this study. Previously the effects of Papaverine have been 
investigated and have shown to have a significant effect on human sperm (Torres-
Flores et al., 2009). However, Torres-Flores et al 2009 investigated levels of cAMP, 
PKA and Ca2+ with the addition of Papaverine. These factors which are closely 
linked with sperm motility, enhanced with the addition of Papaverine. They 
enhanced to such an extent that they were higher than the levels of what PTX (used 
as a positive control) can provoke. However, this study did not investigate the direct 
impact of Papaverine on the percent of motile cells present in a sample. Again, 
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Torres-Flores et al 2009 carried out this study using healthy donors which cannot be 
a comparison for samples with poor motility. The results gained here were from three 
sub-fertile patients. This gives a representation of the effect of using PDE inhibitors 
in a clinical setting.  
 
There was also a significant increase in the percent of motile cells when sperm were 
incubated with BRL. To date, no studies have been carried out using BRL on sperm. 
The importance of these results includes the fact that this is new information with 
regards to the effect of PDEs on patient sperm. These preliminary results emphasise 
the importance of further investigation using PDE inhibitors to overcome the present 
limited knowledge of PDE inhibitors and human sperm. This PDE inhibitor also 
maintained its effect on enhancing the percent of motile cells even after a wash stage. 
The ability of the PDE inhibitor to maintain its effects suggests a clinical advantage 
of the use of BRL in ART as discussed previously (Chapter 3 3.4).  
 
The results gathered in this thesis make it even more surprising that little is known 
about the effects of PDE inhibitors on sperm motility and function. The results from 
this alongside studies previously carried out have demonstrated a strong correlation 
between PDE inhibitors and an improvement in sperm motility. For this reason it is 
important to investigate this further, particularly since the results demonstrated in 
this study involve patient sperm samples. The low number of patient samples used in 
the previous sections are only enough to gain a sense of what effect PDE inhibitors 
have on sperm motility. The next chapter investigates the effect of PDE inhibitors on 
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a larger sperm population in order to gain a better understanding of the percent of the 
population of sub-fertile men which PDE inhibitors have an effect on. 
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Chapter 6: Screening patient samples 
 
6.1 Introduction 
 
Experiments carried out previously in this study have included relatively low sample 
numbers in order to gain an insight into the effect of PDE inhibitors on human sperm 
motility and an indication as to whether motility can be improved. The purpose of 
this chapter was to determine the percent of a sub-fertile male population for each 
IVF and ICSI, which PDE inhibitors have an effect on. Sperm parameters can vary 
dramatically on an individual basis, even between samples from healthy donors 
(Keel, 2006). The aim of this section was to overcome this insufficiency by 
investigating the effect of PDE inhibitors on larger populations of sub-fertile males 
attending ACU Dundee for either IVF or ICSI. In doing so, it was hoped that a better 
understanding may be gained of the extent in which PDE inhibitors improve sperm 
motility. The percentage of progressively motile sperm cells was also analysed in this 
section. Progressive motility is an important factor of sperm motility as it enables 
sperm to penetrate cervical mucus (as discussed in next chapter) and in turn reach the 
oocyte. It is known that fertilisation rates are dependent upon progressively motile 
sperm (Simon and Lewis, 2011) and the assessment of progressive sperm is more 
clinically relevant than slow moving sperm (Lars, 2010). The presence of sperm with 
substantial forward progression is naturally important, whereas clinically this has 
been overcome by ICSI. If PDEs were used clinically with an aim to reduce cost for 
patients and convert what would be ICSI samples now suitable for IVF or IUI after 
PDE inhibitor incubation, it is important to know that the sperm cells being used for 
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the procedure are of fertilising capability. This is hugely important due to the risk of 
fertilisation failure by converting samples which would have undergone manual 
injection to IVF or IUI where sperm must somewhat naturally fertilise the oocyte. 
This section however makes the distinction between slow and rapid cells in IVF and 
ICSI populations by analysing the percentage of progressively motile cells. PDE 
inhibitors Rolipram and BRL were used in this section. Reasons for this include 
Rolipram which is specific to PDE-4 has already been studied in sperm and the aim 
of this was to compare results with studies previously carried out. BRL is used in this 
section as there is no evidence of BRL being used with sperm and thus any result 
here would be novel.  
 
 
6.2 Materials and Methods 
 
ICSI sperm sample preparation 
 
Semen samples from 27 patients consented for research in ACU Dundee were 
collected and prepared within 30 minutes of production by an embryologist. The 
sperm samples were examined including semen volume, concentration and motility 
parameters on the raw semen sample. A maximum of 2.6ml sample was layered on a 
40%/80% PureSperm® density gradient in a 5ml sterile round bottom falcon tube. 
Samples were then centrifuged at 300g for 20 minutes. After centrifugation the 
supernatant was removed with a sterile 5ml falcon glass pipette and the pellet 
removed using a sterile pasture pipette into a sterile 5ml round bottom falcon tube 
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filled with 4ml COOK Sydney IVF Gamete Buffer (SIGB). The pellet was then 
centrifuged at 500g for 10 minutes as a wash step. The media was then removed 
down to roughly 300µl leaving the pellet suspended in the SIGB. A concentration 
check was carried out under Inverted System Microscope Olympus ix51 by simple 
eyeball observation to ensure motile sperm had been recovered. The pellet was then 
left at room temperature conditions until ICSI. After the injection, the sample was 
used in this study. It is the 80% fraction of patient sperm sample that is used in this 
section. 
 
IVF sperm sample preparation 
 
Samples were collected from 33 patients and assessed as above by an embryologist. 
Prior to preparation of IVF suitable sperm, the media used for sperm wash also known 
as Sydney IVF Sperm Media (SISM) is pre-equilibrated overnight at 37°C, 6% CO2. 
Sperm samples were prepared as above using SISM in place of SIGB. Following the 
wash the pellet was then suspended in up to 1ml of SISM. At this stage, another 
sperm assessment was carried out including sperm concentration using a Neubeaur 
chamber which at this point is critical in the calculation for IVF insemination. This 
suspension was hand gassed for approximately 20 seconds using a sterile Hunter 
pipette fitted to the rubber tubing of a 6% CO2 in air gas cylinder. This was left at 
room temperature with the lids sealed until 1 hour before insemination where the lids 
were loosened and samples were placed in a 37°C, 6% CO2 incubator for 1 hour. 
After insemination, samples were used in this study. It is the 80% fraction of patient 
sperm sample that is used in this section. 
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Sperm-PDE inhibitor incubation 
 
After sperm preparation, 99µl of either ICSI or IVF sperm suspensions were placed 
in eppendorfs and 1µl of either Rolipram or BRL at final (concentrations of 10µM 
and 100µM respectively) were added to the samples. The control contained no PDE 
inhibitor. For sperm-PDE inhibitor incubation, IVF samples were placed in a 37°C, 
6% CO2 incubator whereas ICSI samples were left at room temperature conditions. 
The mean percent of motile cells and the mean percent of progressively motile cells 
were recorded with CASA at 1 hour post PDE inhibitor addition as this seems to be 
when PDE inhibitors have the greatest effect. T-test was used in statistical analysis 
and P value <0.05 was considered significant. 
 
 
6.3 Results 
 
There was no significant difference in the mean percent of motile cells between 
control and Rolipram treated 80% fraction of IVF samples after 1 hour incubation 
(mean 77.2% and 75.8% respectively P>0.05) (Figure 6.1). There was however a 
significant increase in the percent of motile cells between control and BRL treated 
IVF samples after 1 hour incubation (mean 77.2% and 85.9% respectively P<0.05). 
The percent of the population of sub-fertile men treated for IVF which were 
positively effected by the use of Rolipram or BRL was 53.3% and 63.3% 
respectively. These figures were derived from raw data.   
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Figure 6.1 Graph demonstrates the mean percent of motile cells from the 80% 
fraction of 33 IVF patient sperm samples with or without the addition of Rolipram or 
BRL after 1 hour incubation period.  
 
 
There was a significant difference in the mean percent of motile cells between 
control and treated following incubation with Rolipram in ICSI samples after 1 hour 
incubation (mean 14.8% and 39.4% respectively P<0.05) (Figure 6.2). There was 
also a significant difference in the mean percent of motile cells between control and 
treated following incubation with BRL in ICSI samples after 1 hour incubation 
(mean 14.8% and 32.0% respectively P<0.05). The percent of the population of sub-
fertile men treated for ICSI positively effected with the use of Rolipram and BRL 
was 96.7% and 98.3% respectively. These figures were derived from raw data.   
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Figure 6.2 Graph demonstrates the mean percent of motile cells from the 80% 
fraction of 27 ICSI patient sperm samples with or without the addition of Rolipram 
or BRL after 1 hour incubation period. 
 
 
There was no statistically significant difference (P>0.05) in the mean percent of 
progressively motile sperm in the 80% fraction of the IVF population when 
incubation with either Rolipram (Figure 6.3) or BRL (Figure 6.4). However there 
was a statistically significant increase (P<0.001) in the percent of progressively 
motile sperm in the 80% fraction of the ICSI population when samples were 
incubated with either Rolipram (Figure 6.5) or BRL (Figure 6.6).  
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Figure 6.3 Graph demonstrates the mean percent of progressively motile cells from 
the 80% fraction of 33 IVF patient sperm samples with or without the addition of 
Rolipram after 1 hour incubation period. 
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Figure 6.4 Graph demonstrates the mean percent of progressively motile cells from 
the 80% fraction of 33 IVF patient sperm samples with or without the addition of 
BRL after 1 hour incubation period. 
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Figure 6.5 Graph demonstrates the mean percent of progressively motile cells from 
the 80% fraction of 27 ICSI patient sperm samples with or without the addition of 
Rolipram after 1 hour incubation period. 
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Figure 6.6 Graph demonstrates the mean percent of progressively motile cells from 
the 80% fraction of 27 ICSI patient sperm samples with or without the addition of 
BRL after 1 hour incubation period. 
 
 
6.4 Discussion 
 
In conclusion to this section, sperm quality of most IVF semen samples is normal. 
Patients attending for IVF treatment are of female factor infertility including 
common causes such as tubular disorders and endometriosis. The sperm sample from 
these couples is generally normal and would probably be IUI if not for the female 
infertility factor. This may therefore be the reason why the effect from incubation 
with PDE inhibitors on IVF sperm (if any) was limited. Patients attending for ICSI 
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treatment are however mainly male factor infertility (as discussed in Chapter 1). The 
low percent of motile cells may mean that there is more room for improvement, 
hence the dramatic increase in percent of motile cells when sperm are incubated with 
PDE inhibitors. The results suggest that PDE inhibitor addition is mainly suitable for 
poor quality sperm, in other words, those attending for ICSI and this is most likely 
the target population.  
 
Based on the WHO criteria, previous studies have mainly examined samples with 
normal semen analyses (Levin et al., 1981; Rees et al., 1990). However, data from 
this thesis supports the study by Yovich et al 1990 suggesting that PDE inhibitors 
may be suited for those with poorer semen analysis. Also supporting this, Tash and 
Means 1983 suggest that highly motile sperm may have a maximally stimulated 
protein kinase A. In turn, with the use of PDE inhibitors an increase in cAMP may 
have no additional effect. This may be concluded by results from thesis where PDE 
inhibitors were added to normal semen samples and there was no change in motility 
(Chapter 2 2.3.1) in contrast to where PDE inhibitors were added to abnormal semen 
samples demonstrating a significant increase in sperm motility (Chapter 2 2.3.2).  
 
Since 11 PDE families now exist, it may be postulated that some are in the sperm 
cell. Selective inhibition of PDEs has allowed enhancement of sperm motility as the 
previous results have demonstrated. While all PDE types have not been identified in 
human sperm, these results show the possible existence of at least five distinct PDE 
forms. This conclusion is supported by this PDE inhibition study when considering 
the percent of each (IVF and ICSI) population is actually effected by the drugs. 
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During inhibition by PDE type specific inhibitors, sperm motility increased. The 
various PDE subtypes (3, 7 and 10) may be located within the human sperm. With 
regards to PDE types 1 and 4, these have already been located within the human 
sperm cell (Fisch., et al 1998). It may therefore be possible that other PDE types may 
be present from these results of sperm activity. 
 
Lastly, it is important to consider the effect of PDE inhibitors on the progressive 
sperm count. The percent of progressively motile cells in the ICSI population 
dramatically increased when sperm were incubated with either Rolipram or BRL. 
These results are of great clinical significance since progressive motility is mainly 
what determines the required procedure for individual samples. For instance, a 
sample of mainly slow moving sperm following preparation would most likely be 
ICSI whereas samples containing a high amount of progressive sperm would be IUI 
(or IVF where female factors contribute to infertility). It is therefore not surprising 
that samples of progressively motile cells have been strongly correlated with 
fertilisation and pregnancy rates (Donnelly et al., 1998). The results from this section 
therefore suggest that in increasing sperm motility of samples from sub-fertile men, 
PDE inhibitors may have a positive effect on sperm function. The next chapter 
explores the effect of PDE inhibitors on the sperm-oocyte interaction. 
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Chapter 7: Investigating the effects of PDE specific inhibitors on human sperm 
function  
 
7.1 Sperm penetration test 
 
7.1.1 Introduction 
 
The interaction between human sperm and cervical mucus is one of the best 
diagnostic tools of male infertility. It has been long known that the functional 
capacity of human sperm in vitro can serve as a better tool in predicting fertility than 
the measurement of traditional semen parameters (Hull et al., 1984; Barratt et al., 
1989; Biljan et al., 1994). Sperm motility is the single most important characteristic 
which should allow penetration and migration within cervical mucus (Mortimer, 
1983). In a normal semen sample, the propulsive forces generated by sperm motility 
thrust the sperm through cervical mucus. The function of cervical mucus is to filter 
out sperm with poor morphology and motility, acting as a barrier to abnormal sperm. 
This is the case for every semen sample, however more so in those with a higher 
abnormal sperm count. Sperm from samples of an asthenozoospermic nature may 
find penetration of cervical mucus difficult due to the lack of progressive propulsion 
(as demonstrated in the ICSI population, Chapter 6 6.3). This is required to enable 
sperm to the vicinity of the oocyte. The difference in the ability of sperm to penetrate 
viscous substances has been previously demonstrated (Barratt et al., 1989). This 
study demonstrated a clear difference between two groups of men (56 semen samples 
in total) with regards to sperm penetration ability with those failing to penetrate 
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cervical mucus also failed to penetrate an oocyte. This study also demonstrated the 
predictive value of the human cervical mucus test (HCM) between fertile and 
infertile men since some semen characteristics were normal yet those sperm failed to 
penetrate cervical mucus and also failed to fertilise an oocyte. This confirmed other 
studies carried out showing positive relationships between in vivo penetration of 
human cervical mucus and in vitro fertilisation of human oocytes (Hull et al., 1984). 
Testing sperm function in vitro is therefore a valuable predictor of fertilisation 
results.  
 
As previously demonstrated, PDE inhibitors do have an effect on sperm motility. 
From this it would be reasonable to assume that PDE inhibitors may also affect 
sperm function. There is limited information regarding the effects of PDE inhibitors 
on sperm function. Nassar et al 1999 used PTX to investigate its effect on human 
sperm motility and bovine cervical mucus penetrability (BCMP). They observed a 
higher BCMP score with asthenozoospermic samples but not with normozoospermic 
samples, again demonstrating the predictive value of this test and demonstrating a 
positive correlation with the BCMP score and samples incubated with PTX. PTX 
enhanced sperm function allowing more sperm to penetrate bovine cervical mucus 
suggesting a potential use of PDE inhibitors for sperm with motility defects. This 
however, seems to be the only study available with information on the effect of PDE 
inhibitors on sperm function. 
 
Traditional semen parameters (mainly concentration, motility and morphology), have 
provided diagnostic information and have predicted fertilisation rates over the years. 
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Although the conventional semen analysis is critical as a tool to diagnose infertility, 
the information gained is limited. Various sperm tests have been investigated to 
determine alternative diagnostic steps in ART including the sperm-cervical mucus 
penetration test. With the addition of PDE type specific inhibitors, sperm-cervical 
mucus tests may not only be a diagnostic tool but a solution for asthenozoospermia 
samples to overcome the issue of reaching the oocyte. 
 
In turn, motility plays an important role in fertilisation by promoting binding of the 
sperm to the zona pellucida and initiation of the acrosome reaction. Motility is 
therefore key in the recognition stage as it provides interaction between gametes. If 
poor quality sperm are then adapted in such a way in which they are enabled to reach 
the egg then the fertilisation potential of poorer semen samples has already been 
enhanced. By the use of PDE inhibitors, increasing motility of sperm would enhance 
the fertilisation potential by increasing the not only the number of sperm at the site of 
fertilisation, but also the number of progressively motile sperm which are more able 
to penetrate viscous media. The next crucial step in predicting successful fertilisation 
is to analyse the journey of the sperm to the oocyte.  
 
 
7.1.2 Materials and Methods 
 
The 80% fraction of 15 patients attending for ICSI treatment was used in this study. 
Semen samples were prepared as described previously (Chapter 6 6.2). Eppendorfs 
of control and treated containing penetration media were prepared (Methylcellulose 
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[MC] at a viscosity of 4000cp, prepared in 10mg/ml in NCB containing 0.45% BSA 
[0.0045g/ml BSA]). Separate eppendorfs of control and treated were then prepared 
and the suspended sample divided between them (~100µl per eppendorf) adding the 
PDE inhibitor Rolipram or BRL to the ‘treated’ eppendorf. Both were covered with 
parafilm to prevent the sample evaporating. Long flattened capillary tubes with a 
length of 5cm and a depth of 0.4mm were placed into each eppendorf containing 
penetration media. Once the tube has filled and excess media wiped from the tubes 
one end of the capillary tube was sealed with plasticine and a distance of 1cm 
marked on the opposite side. The open ends of the capillary tubes were placed in the 
eppendorfs containing the prepared sperm, piercing through the parafilm. Both the 
control and treated eppendorfs were left in 37°C 6% CO2 conditions to allow sperm 
to migrate. A 1 hour incubation period was chosen due the nature of the previous 
results demonstrating that various PDE inhibitors have the greatest effect at this time 
point. The capillary tubes were kept vertical to allow sperm to migrate against 
gravity, mimicking the effects of the female tract. The capillary tubes were then 
removed from the semen samples and wiped to remove residual spermatozoa from 
the surface of the glass. A sperm count was taken using CASA from the 1cm mark 
on the capillary tubes. Readings were taken from 4 fields per plane with a total of 4 
planes. T-test was used in statistical analysis and P value <0.05 was considered 
significant. 
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7.1.3 Results 
 
With the addition of either Rolipram or BRL there was a significant increase 
(P<0.05) in the mean cell number at the 1cm mark on the glass capillary tube (Figure 
7.1.1) from the 80% fraction of ICSI patient sperm. The mean number of cells 
without PDE inhibitor, treated with Rolipram and treated with BRL was 47.5, 145.7 
and 149.7 respectively.  
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Figure 7.1.1 Graph demonstrates the mean number of motile cells at the 1cm mark 
of glass capillary tubes after the 80% fraction of 15 ICSI patient sperm samples were 
incubated with Rolipram, BRL or neither.  
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Figure 7.1.2 Scatter plot demonstrating the number of motile cells from the 80% 
fraction of 15 ICSI patient sperm samples is significantly higher in both Rolipram 
and BRL treated samples when compared with control. 
 
 
The results are further emphasised in figure 7.1.2 showing the number of motile cells 
is considerably higher for each individual patient when treated with Rolipram or 
BRL. 
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7.1.4 Discussion 
 
The sperm penetration test is a well-known and well developed method of testing 
sperm function. It is a predictor of fertilisation outcome through monitoring the 
distance a sperm can travel through a cervical mucus type substance (Barratt et al., 
1989; Ivic et al., 2002). With the addition of PDE inhibitors a comparison can be 
made on how sperm react to this activity. The above results demonstrate that when 
PDE inhibitors are added to an ICSI sperm suspension the effects are significant. A 
significantly greater number of sperm reach the proposed mark when incubated with 
a PDE inhibitor than without. When put into a clinical setting this suggests that 
sperm which have been incubated with the drug have a greater chance of reaching 
the oocyte in vivo than those without. For this to have such an effect on samples 
which are suitable for ICSI, it may resort to them being converted to IVF or even IUI 
if the reason for infertility is predominantly male factor. Overall, this experiment was 
a useful method of determining the fertilisation potential of sperm with or without 
PDE inhibitor. It would appear that not only are PDE inhibitors beneficial for 
enhancing patient sperm motility, they also have a positive effect on sperm function 
by allowing more sperm to penetrate a cervical mucus like substance and presumably 
reach the oocyte. However, although PDE inhibitors appear to have a beneficial 
effect on patient sperm motility and in addition to that, sperm function, it is 
completely unknown as to the effect they would have as sperm reach and interact 
with the oocyte.  
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7.2 Human sperm-zona pellucida binding test  
 
7.2.1 Introduction 
 
Sperm-zona pellucida binding is the best predictor of IVF outcome as it is the first 
crucial step of sperm-oocyte interaction (Oehninger et al., 1992). On binding to the 
oocyte, the zona pellucida acts as an agonist and enables the sperm to undergo 
physiological changes such as the acrosome reaction. With propulsive forces and 
hyperactivation, sperm penetrate the zona pellucida allowing fertilisation to proceed. 
Samples of an abnormal nature however i.e. morphologically abnormal or those with 
a low percentage of progressively motile cells cannot generate these propulsive 
forces required during sperm-oocyte interaction. It has long been known that sperm 
motility is significantly correlated with in vitro fertilisation rates (Liu et al., 1991). 
Reasons for couples attending an assisted conception unit for ICSI include low sperm 
count, high proportion of morphologically abnormal sperm and mainly, due to lack 
of progressive sperm cells. For a small proportion of patients, the reason for having 
ICSI is in fact due to a previous complete fertilisation failure with conventional IVF. 
Roughly 5% of all IVF cases experience failed fertilisation and when the reason is 
explained to the patient as unknown, this may in fact be an issue with sperm binding 
to the zona pellucida.  
 
Sperm-zona pellucida binding tests have been carried out since the late 1970s using 
hamster, pig and human oocytes (Yanagimachi et al., 1979; Green, 1988). The reason 
for such experiments at this time was to gain an understanding of the biological 
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characteristics of the zona pellucida. This is shown in studies such as Tesarik et al 
1988 which investigated the difference in human zona pellucida resistance to sperm 
penetration using oocytes at various stages of maturation. Studies such as this are the 
foundation for our knowledge of the regulation of sperm-oocyte interaction. It was at 
this time that the sperm-zona pellucida interaction was suggested to be a contributing 
factor to unexplained human infertility (Trounson et al., 1980). Today this remains 
the same as demonstrated by Liu et al 2011. This study demonstrated a lower number 
of human sperm bound to the zona pellucida in a group of patients with unexplained 
infertility than those with female factor infertility. The fertilisation rate for the 
unexplained infertility group was also lower than that of female factor. This shows a 
positive relationship between sperm-zona pellucida binding and fertilisation rate. In 
turn, the sperm-zona pellucida binding test is a strong suggestion as a clinical sperm 
function test for patients with unexplained infertility to avoid complete fertilisation 
failure.  
 
Liu, et al. 2011 also discussed the importance of the acrosome during sperm-oocyte 
interaction. They correlated fertilisation rate with induced acrosome reaction where 
the group with the highest number of acrosome reacted sperm also had the lowest 
fertilisation rate. Propulsive forces and hyperactivation are both important factors of 
motility and are crucial for sperm to bind to the zona pellucida. Acrosome reacted 
sperm are an indicator that sperm-zona pellucida interaction has taken place. 
However, premature acrosome reacted sperm cannot fertilise (Liu and Baker., 1990) 
and considering hyperactivated sperm are more likely to acrosome react (Liu et al., 
2007) it is a complete unknown as to the effect any PDE inhibitor would have on this 
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function. On the other hand, acrosome reacted sperm can still penetrate the zona 
pellucida, providing the sperm are in the vicinity of the oocyte. The problem 
therefore lies in defining sperm-zona pellucida binding. Sperm are bound due to the 
fact that the acrosome reaction has taken place, leaving loosely bound sperm to be 
easily unattached from the zona pellucida. Regardless of the definitive, the 
conclusive association of the sperm and the oocyte depend on clinical observations at 
fertilisation checks. With the use of a PDE inhibitor it is possible that poor quality 
sperm may not only be able to reach the oocyte, but more importantly, bind to the 
zona pellucida.  
 
Two bioassays have been developed since the late 1980s known as the hemizona 
assay (HZA) and the sperm-zona binding ratio test, both providing clinical 
information on sperm binding to the zona pellucida in fertile and infertile couples. 
The HZA comprises of two functionally equal zona halves which have been 
microsurgically split. The value of this test is that is provides a comparison between 
the two halves of sperm bound to the same oocyte surface. The test can also be 
performed on a single oocyte which aids the problem of limited oocytes available for 
research. This assay has long been used as a clinical predictor of fertilisation rates, 
identifying those patients likely to encounter fertilisation problems during IVF 
(Franken et al., 1989). The other sperm-zona pellucida binding test uses oocytes 
which have failed to fertilise during IVF. With two different sperm populations 
(fertile and infertile) labelled with fluorescent dye, they are mixed with a group of 
oocytes and incubated. Oocytes are then assessed for tightly bound sperm. The 
problem with this type of study is the high number of oocytes required. Below is an 
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example of a single sperm cell binding to the zona pellucida of a Metaphase 1 oocyte 
(Figure 7.2.1). Here the sperm head can clearly be seen as it makes contact with the 
zona pellucida. This depicts the initial stages of sperm-oocyte interaction and is one 
of the most important steps in human fertilisation. 
 
 
 
Figure 7.2.1 Sperm-zona pellucida binding. The initial stages of sperm-oocyte 
interaction. 
 
 
This final section of the study aims to determine the effect of PDE inhibitors on 
sperm-oocyte interaction by investigating sperm-zona pellucida binding after ICSI 
patient sperm are incubated with Rolipram. The creation of this technique was 
inspired by personal experience in ACU Dundee which provided a sense of clinical 
application for this study. 
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7.2.2 Materials and Methods 
 
Human oocytes were obtained through consenting patients in the ACU Ninewells 
Hospital attending oocyte collection prior to ICSI treatment only. Those undergoing 
IVF were not used in this study as the oocytes are not assessed prior to insemination 
and all oocytes are used in treatment. Patients suitable for ICSI were also chosen as 
immature oocytes are identifiable on the day of oocyte collection and not used for 
injection. Oocytes which were not suitable for treatment i.e. germinal vesicle (GV) 
and metaphase 1 (M1) stage oocytes, were therefore kept aside for experimental 
purposes and used in this study fresh on the day of oocyte retrieval.  
 
After the Embryologist performing the ICSI procedure selects the oocytes suitable 
for ICSI, GV and M1 oocytes were left in 5µl SIGB drops with a 3.0ml overlay of 
Sydney IVF culture oil (SICO) in the ICSI injection dish at 37°C. An ICSI dish was 
equilibrated at 37°C, 6% CO2 for 4 hours containing the required number of 5µl 
drops of SIFM, some of which were wash drops and others were control and treated 
drops which will eventually contain the sperm and dissected zona pellucida. This was 
covered with a 3.0ml SICO overlay.  
 
During dish equilibration, the sperm suspension from the male partner was used after 
the ICSI procedure was carried out. The sperm already suspended in approximately 
0.3ml of SIGB was made up to 1ml of SIGB kept at room temperature and a sperm 
count was taken with a Neubeaur chamber to determine the concentration required 
(20M/ml standard). This was then centrifuged at 300g for 5 minutes to gain a pellet. 
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The SIGB after the wash was taken off using a glass pipette and the pellet was 
suspended in up to 1ml of hand gassed (6% CO2) SISM. This was left for 3 hours at 
room temperature for the sperm to initiate capacitation prior to zona-binding, 
mimicking our clinical IVF procedure. Following this, the sperm suspension was 
centrifuged at 300g for 5 minutes and suspended in SIFM. Two eppendorfs (control 
and treated) from this sperm suspension were prepared, each containing 99µl of the 
sperm suspension with one containing 1µl of Rolipram at a final concentration of 
10µM. The control and treated SIFM drops within the dish were then taken out and 
replaced with 5µl of each the control and treated samples from the eppendorfs.  
 
GV and M1 oocytes were dissected in their injection dish using insulin needles. The 
ooplasmic contents of the oocytes were released and the empty zonas were split as 
close to equal halves as possible (Figure 7.2.2). The zona halves were then taken 
through the wash drops within the equilibrated dish to remove HEPES based media 
and each half was placed in the sperm-SIFM drops. The dish containing both sperm 
and zona pellucida was left in 37°C, 6% CO2 conditions for 2 hours giving the sperm 
sufficient time to bind to the zona pellucida. After this time the zona pellucida halves 
were aspirated through more wash drops to remove loosely bound sperm. Whilst in 
the last wash drops the dish was placed on the stage of Inverted System Microscope 
Olympus ix51 and observed at 40x magnification (Figure 7.2.3). Images were 
obtained through the computer. Wilcoxon matched pairs signed ranks test was used 
in statistical analysis and a P value of <0.05 was considered significant. 
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Figure 7.2.2 Figure demonstrates 8 zona pellucida halves before being placed into 
wash drops with sperm 
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. 
Figure 7.2.3 Figure demonstrates magnified observation of sperm binding to zona 
pellucida. 
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Figure 7.2.4 Figure demonstrates Hemi-Zona Assay 
 
 
7.2.3 Results  
 
The results of sperm-zona pellucida binding with and without Rolipram are 
demonstrated in table 7.1. Figures presented represent the actual number of sperm 
tightly bound to each zona pellucida half. Visual examples from two oocytes are also 
demonstrated below (Figures 7.2.5 and 7.2.6). 
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Table 7.1 Demonstrating the number of sperm bound to each human zona pellucida. 
Sperm incubated with or without Rolipram. 
Oocyte Number Control or 
Treated half of 
zona pellucida 
Number of sperm bound to 
zona pellucida 
1 Control  
Rolipram  
18 
28 
2 Control  
Rolipram 
20 
27 
3 Control  
Rolipram 
3 
2 
4 Control  
Rolipram  
5 
7 
5 Control  
Rolipram 
1 
0 
6 Control  
Rolipram 
0 
3 
7 Control  
Rolipram 
2 
4 
8 Control  
Rolipram 
4 
2 
9 Control  
Rolipram 
8 
10 
10 Control  
Rolipram 
22 
28 
11 Control  
Rolipram 
7 
5 
12 Control  
Rolipram 
13 
16 
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Figure 7.2.5 Demonstrating results from oocyte number 5 (see Table 1) a zona 
pellucida half with one sperm bound to the control (A) and no sperm bound to the 
treated half (B). 
 
 
 
Figure 7.2.6 Demonstrating results from oocyte number 8 (see Table 7.1) a zona 
pellucida half with four sperm bound to the control (A) and two sperm bound to the 
treated half (B). 
 
 
A B 
A B 
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Figure 7.2.7 Graph demonstrates the mean number of sperm bound in to the zona 
pellucida of control and Rolipram treated groups.  
 
 
There was a significant difference (P<0.05) in the number of sperm bound to the 
zona pellucida between the 80% fraction of ICSI sperm samples with and without the 
addition of Rolipram (mean 8.58 and 11.0 respectively).   
 
 
7.2.4 Discussion 
 
Sperm-zona pellucida binding is a well established technique used to predict the 
fertilisation potential and pregnancy outcome within infertile couples (Arslan et al., 
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2006). This technique which has been carried out since the late 80s has been applied 
clinically to determine the fertilising competence of human sperm. The results above 
demonstrate a significant improvement in the number of sperm bound to human zona 
pellucida with the use of Rolipram.  
 
One of the reasons patients undergo ICSI treatment is due to previous IVF 
fertilisation. Sperm may be incapable of binding to the zona pellucida and fusing 
with the oocyte due to poor motility and abnormal morphology. Embryologists have 
been able to overcome this barrier since ICSI was introduced in 1992. Whenever 
there is clinical doubt on the quality of a sperm sample, it is usually converted to 
ICSI, costing more money for the patient (if self-funding), more time consumed for 
the procedure and an increased risk of damaging the oocyte. If there are substances 
which provide known improvement in sperm quality, enhancing the fertilising 
potential of sperm, this quick judgement may not always be the case.  
 
The molecular basis for which sperm binds to the zona pellucida is still an 
unresolved issue as the complete binding process has not yet been explained. 
Carbohydrate sequences on the zona pellucida have recently been determined (Pang 
et al., 2011) and proteins located on the sperm surface relating to zona pellucida 
binding have also been found (Redgrove et al., 2011). Insights into the molecular 
mechanisms that govern sperm-oocyte interaction are becoming apparent and the 
technique of sperm-zona pellucida binding is becoming further implicated, 
particularly in predicting fertilisation outcome. However, due to the limitations of 
access to ART laboratory equipment, knowledge of techniques and the ability to 
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research, this technique is rarely carried out for research purposes. Sperm-zona 
binding has never been investigated with regards to PDE inhibitors and their effects. 
This is a novel approach to investigate the effect of PDE inhibitors on sperm 
function. The results gained in this section suggest that sperm are more capable of 
binding to the zona pellucida after incubation with Rolipram. Since the sperm-zona 
binding technique is a well known predictor of fertilisation it may be suggested that 
with an increase in the number of sperm bound to the zona pellucida after incubation 
with Rolipram, an increase in fertilisation rate may occur. The clinical value of the 
addition of PDE inhibitors could add new tests to assess a couple’s potential for 
fertilisation (e.g. semen analysis) or may in fact be used as a clinical step in sperm 
preparation with the view to improving success rates. 
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Chapter 8: General Discussion 
 
The results in this study demonstrate a number of facts about the effect of PDE 
inhibitors on human sperm motility and function.  
 
Incubating sperm with PDE inhibitors clearly increases the motility of samples from 
sub-fertile men attending an assisted conception unit for ICSI, predominantly the 
male factor infertility procedure. The clinical value of this is highly significant 
considering almost half of all ART procedures are of male factor infertility. The 
main element to male sperm inefficiency is poor motility and if enhanced, this could 
provide great potential for the couple and the clinic. An increase in sperm motility 
suggests an improvement. This may include the fertilisation potential for the couple 
and the alternative of a less time consuming procedure for the embryologist. In the 
past, it has been reported that PDE inhibitors do not have a positive effect of sperm 
motility. These studies however, have used samples collected from healthy sperm 
donors whose sperm, as shown in this study, cannot be improved as the number of 
motile cells is already high. The topic of PDE inhibitors and human sperm is still 
debatable and requires further investigation; however the basis for the evidence of 
the improvement of sperm samples with these inhibitors is already there.  
 
This study then examined the potential of PDE inhibitors having a negative effect on 
sperm physiology. Although the importance of the stage of the acrosome reaction 
during sperm-oocyte interaction is to date clearly controversial, it was established 
that in this case induction of the acrosome reaction by PDE inhibitors would be a 
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negative effect. The acrosome of sperm incubated with PDE inhibitors remained 
intact in this study. It is unknown as to whether this is a beneficial effect as although 
PDE inhibitors do not seem to induce it, the acrosome reaction is a crucial step in the 
process of fertilisation and it is not known whether incubation with PDE inhibitors 
may in fact prevent it. Further studies are required to investigate the exact effect of 
PDE inhibitors on the state of sperm acrosome. Further to this, sperm DNA was 
examined to determine whether any damage is caused when sperm are incubated 
with PDE inhibitors. It would seem as though PDE inhibitors do not induce any 
damage to sperm cell DNA. Tests such as this are crucial to establish the clinical 
benefits of using PDE inhibitors during ART procedures. Besides the benefits PDE 
inhibitors have on sperm motility, to learn that they have a negative effect on sperm 
DNA would rule them out from clinical use completely. The results in this study 
demonstrate no negative effects of the drugs on sperm DNA. However, the TUNEL 
assay is a controversial technique as it is not a reliable test. More investigation would 
be required to determine any negative effects PDE inhibitors have on human sperm.  
In this study sperm were then incubated with PDE inhibitors which have limited or 
no previous information. This was a novel approach to investigate the effect of PDE 
inhibitors on sperm motility as the previously used inhibitors (8-MeOM-IBMX and 
Rolipram) have already been studied. Milrinone, BRL and Papaverine which have 
not been extensively studied previously showed similar effects on sperm motility. 
These are encouraging results for future investigation. Non-specific inhibitors such 
as PTX have been extensively studied and it is well known that they have positive 
effects on sperm motility. Table 8.1 demonstrates some of the studies which have 
investigated this inhibitor at a clinical level giving the fertilisation and pregnancy 
 
 
 
 
135 
rates with the use of PTX. The significance values are in comparison to those without 
the PDE inhibitor. In comparison to PTX, very little is known of the effect of other 
PDE inhibitors on human sperm motility and function. The results in this thesis 
however are encouraging and provide an incentive to advance with the investigation 
of PDE inhibitors on human sperm motility.  
 
Further from this, human sperm function was investigated to determine if PDE 
inhibitors not only give a positive effect on sperm motility, but sperm function in 
relation to the steps leading to fertilisation. The sperm penetration test was used to 
establish whether sperm are more able to swim through viscous media when 
incubated with PDE inhibitors. This mimics the journey of sperm to the oocyte 
through the female reproductive tract, an important step leading up to sperm-oocyte 
interaction. The results demonstrate there is a significant increase in the number of 
sperm at a marked distance when sperm have been incubated with PDE inhibitors. 
Reasons for this may include the fact that sperm swim faster when incubated with 
PDE inhibitors and are therefore more capable of dealing with viscosity than those 
without. These results show a positive relationship between PDE inhibitors and 
human sperm function. However, although more sperm may be able to reach a 
required distance, and possibly the oocyte in vivo, this does not necessarily mean 
PDE inhibitors aid sperm-oocyte interaction, the most important step in fertilisation.  
A novel approach was taken to investigate the effect of PDE inhibitors on the ability 
of sperm to bind to human oocyte zona pellucida. Sperm-zona pellucida binding has 
previously been used as a way of predicting fertilisation. This is a well known 
technique which has mainly been carried out using cadaver or animal oocytes. 
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Studies have tested this technique on human oocytes including this thesis. However, 
not many studies have carried out sperm-zona pellucida binding using resources from 
an assisted conception unit, techniques so closely applied to daily clinical work and 
patients attending the clinic for treatment. It is important to mention these are 
modern resources and techniques which would not have been available when these 
previous studies were carried out. Further to this, no studies have examined the effect 
of PDE inhibitors on the ability of sperm to bind to human oocyte zona-pellucida in 
this situation. The results in this thesis suggest that PDE inhibitors have a positive 
effect on the ability of sperm to bind to the zona pellucida since more sperm were 
found bound after incubation with a PDE inhibitor. These results are again 
encouraging and give reason to investigate the effects of PDE inhibitors on human 
fertilisation. There were many difficulties with this technique. One of the problems 
and probably the most important was the use of germinal vesicle and metaphase I 
oocytes. Since metaphase II oocytes are used in the ART procedures of patient 
treatment, this is the closest to mimicking the actual IVF procedure. Results gained 
may therefore not be truly accurate of what would occur naturally as it is known 
immature oocytes do not fertilise. This may be the reason for the observation of such 
low sperm numbers bound to the zona pellucida. Overall, this technique was as 
accurate as possible with the aim of gaining enough information to determine 
whether PDE inhibitors have a negative effect on the ability of sperm to bind to the 
zona pellucida. These preliminary results demonstrate that sperm still bind in the 
presence of the inhibitor. 
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It is unlikely going by the results gained that PDE inhibitors cause a negative effect 
on the ability of sperm to bind to the zona pellucida, however further investigation is 
required in addition to these preliminary results to establish PDE inhibitors as 
clinically viable.  
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Appendix 
 
Investigating the effects of phosphodiesterase inhibitors on human sperm 
motility and function 
 
Repeated measures ANOVA was used to assess the effect of phosphodiesterase 
inhibitors over 0.5, 1 and 2 hour incubation periods and students paired t-test where 
readings were taken at 1 hour only. Statistical tests were carried out in SPSS version 
19. 
 
2.3.1 Effect of PDE inhibitors on ‘healthy’ donor population 
8-MeOM-IBMX on 80% fraction donor  
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Figure 1. Graph demonstrates the mean percentage of progressively motile cells 
(±SEM) in the 80% fraction of donor samples with or without 8-MeOM-IBMX after 
0.5, 1 and 2 hour incubation. There was no statistically significant difference 
between control and treated at any time point (P=0.798). 
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Figure 2. No differences could be found between VAP levels recorded over time 
(ANOVA P=0.530) for the 80% fraction of donor samples with or without 8-MeOM-
IBMX after 0.5, 1 and 2 hour incubation.  
 
 
 
Rolipram on 80% fraction donor 
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Figure 3. Graph demonstrates the mean percentage of progressively motile cells 
(±SEM) in the 80% fraction of donor samples with or without Rolipram after 0.5, 1 
and 2 hour incubation. There was no statistically significant difference between 
control and treated at any time point (P=0.697). 
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Figure 4. There was no statistical difference between VAP of control and treated 
over time (ANOVA P=0.911) for the 80% fraction of donor samples with or without 
Rolipram after 0.5, 1 and 2 hour incubation.  
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Figure 5. Graph demonstrates the mean percentage of progressively motile cells 
(±SEM) in the 40% fraction of donor samples with or without 8-MeOM-IBMX after 
0.5, 1 and 2 hour incubation. There was no statistically significant difference 
between control and treated at any time point (P>0.05). 
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Figure 6. Graph demonstrates the effect of 8-MeOM-IBMX on the average path 
velocity of the 40% fraction of donor samples (n=3) over time. There is no 
statistically significant difference between control and treated over time (P=0.668).
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Figure 7. Graph demonstrates the mean percentage of progressively motile cells 
(±SEM) in the 40% fraction of donor samples with or without Rolipram after 0.5, 1 
and 2 hour incubation. There was no statistically significant difference between 
control and treated at any time point (P>0.05). 
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Figure 8. Graph demonstrates the effect of Rolipram on the average path velocity of 
the 40% fraction of donor samples (n=3) over time. There is no statistically 
significant difference between control and treated over time (P=0.347). 
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Figure 9. Graph demonstrates the mean percentage of motile cells in the 80% 
fraction of patient samples with or without 8-MeOM-IBMX after 0.5, 1 and 2 hour 
incubation. There was no statistically significant difference between control and 
treated at any time point (P>0.05).  
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Figure 10. Graph demonstrates the mean percentage of progressively motile cells in 
the 80% fraction of patient samples with or without 8-MeOM-IBMX after 0.5, 1 and 
2 hour incubation. There was no statistically significant difference between control 
and treated at any time point (P>0.05). 
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Figure 11. Graph demonstrates the effect of 8-MeOM-IBMX on the average path 
velocity of the 80% fraction of patient samples (n=3) over time. There is a 
statistically significant difference between control and treated over time (P<0.000). 
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Figure 12. Graph demonstrates the mean percentage of motile cells in the 80% 
fraction of patient samples with or without Rolipram after 0.5, 1 and 2 hour 
incubation. There was no statistically significant difference between control and 
treated at any time point (P>0.05). 
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Figure 13. Graph demonstrates the mean percentage of progressively motile cells in 
the 80% fraction of patient samples with or without Rolipram after 0.5, 1 and 2 hour 
incubation. There was no statistically significant difference between control and 
treated at any time point (P>0.05). 
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Figure 14. Graph demonstrates the effect of Rolipram on the average path velocity 
of the 80% fraction of patient samples (n=3) over time. There is a statistically 
significant difference between control and treated over time (P<0.000). 
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Figure 15. Graph demonstrates the mean percentage of progressively motile cells in 
the 40% fraction of patient samples with or without 8-MeOM-IBMX after 0.5, 1 and 
2 hour incubation. There was a statistically significant difference between control 
and treated at each time point (P<0.001). 
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Figure 16. Graph demonstrates the effect of 8-MeOM-IBMX on the average path 
velocity of the 40% fraction of patient samples (n=3) over time. There is a 
statistically significant difference between control and treated over time (P<0.001). 
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Figure 17. Graph demonstrates the mean percentage of progressively motile cells in 
the 40% fraction of patient samples with or without Rolipram after 0.5, 1 and 2 hour 
incubation. There was a statistically significant difference between control and 
treated at each time point (P<0.001). 
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Figure 18. Graph demonstrates the effect of Rolipram on the average path velocity 
of the 40% fraction of patient samples (n=3) over time. There is a statistically 
significant difference between control and treated over time (P<0.001).P<0.001 
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Controls 
 
Figure 19. Graph demonstrates effect of DMSO on the mean percentage of motile 
cells in the 40% and 80% fraction of patient samples (n=3) with or without Rolipram 
after 1 hour incubation. There was no significant difference between control and 
treated in either the 40% or 80% fraction (P=0.713 and P=0.550 respectively). 
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Figures from presentation 
 
 Figure 20. Figure demonstrating the effect of PDEI-1 (8-MeOM-IBMX) and PDEI-
4 (Rolipram) on the % of motile cells on the 40 and 80% fractions of donor samples 
(n=3). There is no significant difference between: 
PDEI-1 40% (P=0.608) 
PDEI-1 80% (P=0.893) 
PDEI-4 40% (P=0.608) 
PDEI-4 40% (P=0.098) 
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 Figure 21. Figure demonstrating the effect of PDEI-1 (8-MeOM-IBMX) and PDEI-
4 (Rolipram) on the % of progressively motile cells in the 40 and 80% fractions of 
donor samples (n=3). There is no significant difference between: 
PDEI-1 40% (P=0.295) 
PDEI-1 80% (P=0.387) 
PDEI-4 40% (P=0.818) 
PDEI-4 40% (P=0.147) 
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Figure 22. Figure demonstrating the effect of PDEI-1 (8-MeOM-IBMX) and PDEI-4 
(Rolipram) on the average path velocity in the 40 and 80% fractions of donor 
samples (n=3). There is no significant difference between: 
PDEI-1 40% (P=0.452) 
PDEI-1 80% (P=0.311) 
PDEI-4 40% (P=0.566) 
PDEI-4 40% (P=0.169) 
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 Figure 23. Figure demonstrating the effect of PDEI-1 (8-MeOM-IBMX) and PDEI-
4 (Rolipram) on the % motile cells in the 40 and 80% fractions of patient samples 
(n=3). There was a significant difference between the 40% fraction but not the 80%: 
PDEI-1 40% (P<0.000) 
PDEI-1 80% (P=0.893) 
PDEI-4 40% (P=0.008) 
PDEI-4 40% (P=0.418) 
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Figure 24. Figure demonstrating the effect of PDEI-1 (8-MeOM-IBMX) and PDEI-4 
(Rolipram) on the % progressively motile cells in the 40 and 80% fractions of patient 
samples (n=3). There was a significant difference between the 40% fraction but not 
the 80%: 
PDEI-1 40% (P<0.000) 
PDEI-1 80% (P=0.149) 
PDEI-4 40% (P<0.000) 
PDEI-4 40% (P=0.591) 
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 Figure 25. Figure demonstrating the effect of PDEI-1 (8-MeOM-IBMX) and PDEI-
4 (Rolipram) on the average path velocity in the 40 and 80% fractions of patient 
samples (n=3). There was a significant difference between control and treated in all 
fractions 
PDEI-1 40% (P<0.000) 
PDEI-1 80% (P=0.003) 
PDEI-4 40% (P=0.009) 
PDEI-4 40% (P=0.013) 
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Figure 26. Figure demonstrating the effect of PDEI-1 (8-MeOM-IBMX). PDEI-3 
(Milrinone), PDEI-4 (Rolipram) PDEI-7 (BRL) and PDEI-9 (Papaverine) on the % 
motile cells in the 40 fraction of patient samples (n=3). There was a significant 
difference between control and treated using all inhibitors: 
PDEI-1 (P<0.000) 
PDEI-3 (P<0.000) 
PDEI-4 (P=0.008) 
PDEI-7 (P<0.000) 
PDEI-9 (P<0.000) 
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Figure 27. Figure demonstrating the effect of PDEI-4 (Rolipram) on the % motile 
cells in the 40 and 80% fractions of patient IVF samples (n=33). There was a 
significant difference between the 40% fraction but not the 80%: 
40% (P<0.000) 
80% (P=0.543) 
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 Figure 28. Figure demonstrating the effect of PDEI-4 (Rolipram) on the % 
progressively motile cells in the 40 and 80% fractions of patient IVF samples (n=33). 
There was a significant difference between the 40% fraction but not the 80%: 
40% (P=0.012) 
80% (P=0.141) 
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 Figure 29. Figure demonstrating the effect of PDEI-4 (Rolipram) on the average 
path velocity in the 40 and 80% fractions of patient IVF samples (n=33). There was a 
significant difference between the 40% fraction but not the 80%: 
40% (P=0.018) 
80% (P=0.826) 
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 Figure 30. Figure demonstrating the effect of PDEI-4 (Rolipram) on the % motile 
cells in the 40 and 80% fractions of patient ICSI samples (n=27). There was a 
significant difference between the 40% fraction and the 80%: 
40% (P<0.001) 
80% (P<0.001) 
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 Figure 31. Figure demonstrating the effect of PDEI-4 (Rolipram) on the % 
progressively motile cells in the 40 and 80% fractions of patient ICSI samples 
(n=27). There was a significant difference between the 40% fraction and the 80%: 
40% (P<0.001) 
80% (P<0.001) 
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 Figure 32. Figure demonstrating the effect of PDEI-4 (Rolipram) on average path 
velocity in the 40 and 80% fractions of patient ICSI samples (n=27). There was a 
significant difference between the 40% fraction and the 80%: 
40% (P<0.001) 
80% (P<0.001) 
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Figure 33. Figure demonstrating the effect of an additional wash step with PDEI-4 
(Rolipram) on the % motile cells in the 40 and 80% fractions of patient samples 
(n=3). There was no significant difference 
40% (P=0.179) 
80% (P=0.896) 
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Figure 34. Figure demonstrating the effect of an additional wash step with PDEI-4 
(Rolipram) on the % progressively motile cells in the 40 and 80% fractions of patient 
samples (n=3). There was no significant difference 
40% (P=0.476) 
80% (P=0.483) 
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CASA 
 
The following data demonstrates the reliability and reproducibility of using CASA 
throughout experiments. It is recognised that a number of variables exist with the use 
of CASA which may affect the overall result. The following results serve as a control 
for this study. 
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Figure 35. Graph demonstrates a comparison of concentration counts using CASA 
or haemocytometer. Error bars of standard deviation represent four counts of a 
minimum of 800 cells. There were no significant differences between counts for each 
donor (student’s paired t-test P=0.983, 0.735, 0.834 and 0.896).  
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Figure 36. Graph demonstrates a comparison of progressive motility counts using 
CASA or haemocytometer. Error bars of standard deviation represent four counts of 
a minimum of 800 cells. There were no significant differences between counts for 
each donor (student’s paired t-test P=0.785, 0.587, 0.564 and 0.649).  
 
 
 
 
 
